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ABSTRACT 
With an increased demand to supply food to an ever-increasing world population the 
application of new technologies to improve animal production efficiency has become a global 
priority. A balance must be found however between the production benefit of these 
technologies, animal welfare and human safety. 
The purpose of the two studies undertaken was to determine the target animal tolerance of R-
salbutamol when included in feed, the remaining residues in liver, kidney, muscle and fat 
following various withdrawal periods, and the withdrawal period at which animal tissue will be 
safe for human consumption. 
To determine the withdrawal period, the residues detected in animal tissue must be compared 
to the Acceptable Daily Intake (ADI) of R-salbutamol in humans.  As no extensive toxicological 
evaluation has ever been done for R-salbutamol, a complete evaluation of available 
toxicological data was performed.  Repeat dose studies, carcinogenicity, genotoxicity, 
reproductive, foetal and acute toxicity data were evaluated to determine the ADI. No 
carcinogenicity, genotoxicity or reproductive toxicity were noted for R-salbutamol.  Long-term 
effects were observed with a No Adverse Effect Level (NOAEL) of 12 mg/kg BWt. Foetal 
toxicity (teratology) were noted at high inclusion levels in rabbits (cranioschisis at 50 mg 
salbutamol/kg BWt) with a NOAEL of 10.75 mg/kg derived from a rat teratology study.   The 
Acute Reference Dose (ARfD), derived from human studies, was however the lowest safe 
level with a NOAEL (also referred to as the point of departure (POD)) of 1mg R-salbutamol/kg 
BWt, due to the possible acute effects of R-salbutamol ingestion at higher inclusion levels.  An 
ARfD of 3 µg/kg BWt were calculated and used as the upper limit of the ADI, which was 
determined to be 0 - 3 µg/kg BWt in humans.     
The lamb feedlot study included 13 lambs; one lamb being slaughtered at the start of the trial 
as control.  The remaining 12 lambs were treated with 21 mg R-salbutamol per day (0.5 mg/kg 
BWt) for 28 days. R-salbutamol was withdrawn from the feed 7 hours prior to slaughter for 6 
of the lambs and withdrawn for 24 hours from the feed for the remaining 6 lambs. Liver, kidney, 
muscle and fat samples were collected at slaughter and analysed for parent and total 
salbutamol (parent + metabolites) residues. Heart rate, rectal temperature and respiratory rate 
were measured before the start of the medicated period (study day -1) and again on day 28 
of the medicated period. 
Heart rate did not differ between day -1 and 28, but respiratory rate and rectal temperature 
were both higher at day 28 compared to day -1 (P < 0.05).  The increase in rectal temperature 
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was not clinically significant as it remained within normal parameters. The increase in 
respiratory rate in 7 of the 12 lambs was attributed to lower respiratory tract infection.  
Parent salbutamol residues in lambs were the highest in the liver (± 89% of residues detected) 
at 7 hours withdrawal, followed by the kidney (± 7%), fat (± 2.5%) and muscle (± 1%). The 
residue concentrations at 24 hours after withdrawal were less than 50% of the levels detected 
at 7 hours following withdrawal. Metabolism of R-salbutamol is rapid following absorption due 
to high pre-systemic metabolism as indicated by the high level of metabolites detected 
following hydrolysis of tissue samples with β-glucoronidase. At 7 hours after withdrawal, 44% 
of the total residues were present as parent salbutamol in the liver and 39% at 24 hours after 
withdrawal. In the kidney 28% and 30% of parent salbutamol were detected at 7 hours and 24 
hours, respectively as a percentage of total salbutamol. Muscle had 47% parent salbutamol 
as a percentage of total salbutamol at 7 hours after withdrawal. The percentage reduced to 
17% after 24 hours withdrawal. In fat, 11% of total salbutamol were present as parent 
salbutamol at 7 hours and 14% 24 hours after withdrawal. 
The theoretical maximum daily intake of salbutamol for humans calculated from the lamb 
residue data is less than 10% (16.88 µg/day) of the acceptable daily intake (ADI) (180 µg/kg 
BWt in adult human). Animal tissue from feedlot lambs fed R-salbutamol, according to label 
recommendations, with zero withdrawal in feed, will provide adequate consumer protection. 
In a similar study performed in beef cattle one group of four cattle received non-medicated 
feed as the negative control group. Three groups of six cattle each received 150 mg R-
salbutamol/head/day (0.42 mg/kg BWt) in feed for 44 days. One animal from the control group 
was slaughtered on study day 3. The three medicated groups were slaughtered on <12-, 24- 
and 48-hours following withdrawal of R-salbutamol from feed respectively together with one 
each of the control group. The control animals were included to show that there were no 
residues occurring naturally within the test herd. Liver, kidney, muscle and fat samples were 
collected and analysed for salbutamol residues. No residues were detected for total 
salbutamol (LOQ = 3 μg/kg) in any of the tissues. No visual adverse events were observed in 
the study animals and R-salbutamol was well tolerated in feedlot cattle. 
From the data in this study MRL for R-salbutamol is therefore suggested to be set for liver at 
300 µg/kg, muscle at 6.5 µg/kg, kidney at 40 µg/kg and fat at 13 µg/kg. At these levels the 
daily intake of residue will still be below 20% of the ADI. 
Stellenbosch University  https://scholar.sun.ac.za
v 
Further investigation into intravenous and oral pharmacokinetics of R-salbutamol in both 
lambs and cattle will be beneficial to better understand the absorption, distribution, metabolism 
and excretion of R-salbutamol in feedlot lambs and cattle. 
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OPSOMMING 
Met die toenemende vraag na voedsel vir 'n steeds toenemende wêreldbevolking, het die 
toepassing van nuwe tegnologie om die doeltreffendheid van diereproduksie te verbeter, 'n 
wêreldwye prioriteit geword. Daar moet egter ‘n balans gevind word tussen die produksie 
voordele van hierdie tegnologie, dierewelsyn en menslike veiligheid. 
Die doel van die twee studies wat onderneem is, was om die veiligheid van R-salbutamol te 
bepaal in die teiken diere na voer insluiting, die oorblywende residue te bepaal in lewer, niere, 
spier en vet na aanleiding van verskillende onttrekkingsperiodes en die onttrekkingstydperk 
waar dierlike weefsel veilig sal wees vir menslike gebruik. 
Om die onttrekkings periode te kan bepaal, moet die residue wat waargeneem is in die dierlike 
weefsel vergelyk word met die aanvaarbare daaglikse inname (ADI) vir R-salbutamol in 
mense.  Geen ekstensiewe toksikologiese evaluasie is al ooit vir R-salbutamol gedoen nie. 
Gevolglik is ‘n volledige evaluasie hier gedoen op die beskikbare toksikologiese data. 
Herhaalde dosis studies, karsinogenisiteit, genotoksisiteit, reproduktiewe, fetale en akute 
toksisiteitsdata is geëvalueer om die ADI te bepaal. Geen karsinogeniese, genotoksiese of 
reproduktiewe toksisiteit is vir R-salbutamol opgemerk nie. Langtermyn effekte is waargeneem 
met 'n Geen Negatiewe Effek Vlak (NOAEL) van 12 mg/kg LM. Fetale toksisiteit (teratologie) 
is op hoë insluitingvlakke aangetoon in konyne (kranioskise teen 50 mg salbutamol/kg LM) 
met 'n NOAEL van 10,75 mg/kg LM, wat afgelei is van 'n rot teratologie studie. Die akute 
verwysingsdosis (ARfD), afgelei van menslike studies, was egter die laagste veilige vlak met 
‘n NOAEL (ook verwys na as die Vertrek Punt (POD)) van 1 mg R-salbutamol/kg LM, as gevolg 
van die moontlike akute effekte as gevolg van inname van R-salbutamol. ‘n ArfD van 3 μg/kg 
LM is bereken en gebruik as die boonste limiet van die ADI, vasgestel as 0 - 3 μg/kg LM in 
mense.  
Dertien lammers is in the die eerste studie ingesluit; een lam is aan die begin van die studie 
as kontrole dier geslag. Die oorblywende 12 lammers is vir 28 dae behandel met 21 mg R-
salbutamol per dag (0.5 mg/kg LM). R-salbutamol is 7 uur voor slag by 6 van die lammers uit 
die voer onttrek en onttrek vir 24 uur voor slag in die oorblywende 6 lammers. Lewer-, nier-, 
spier- en vet monsters is by slag ingesamel en geanaliseer vir biointakte en totale salbutamol 
(biointakte + metaboliete) residue. Hartklop, liggaamstemperatuur en respirasietempo is voor 
die aanvang van die medikasie periode (studie dag -1) en weer op dag 28 van die medikasie 
periode gemeet. 
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Geen verskil is waargeneem in hartklop tempo tussen dag -1 en 28 nie, maar respirasietempo 
en liggaamstemperatuur was beide hoër op dag 28 in vergelyking met dag -1 (P <0.05). Die 
toename in rektale temperatuur was nie klinies beduidend nie, aangesien dit binne normale 
parameters gebly het. Die toename in respiratoriese tempo in 7 van die 12 lammers is 
toegeskryf aan lae respiratoriese infeksie.  
Biointakte salbutamol residue in lammers was die hoogste in lewer (± 89% van residue) by 7 
uur onttrekking, gevolg deur nier (± 7%), vet (± 2,5%) en spier (± 1%). Die residu konsentrasies 
24 uur na onttrekking was minder as 50% van die vlakke wat op 7 uur na onttrekking gemeet 
is. R-salbutamol metaboliseer vinnig na absorpsie as gevolg van hoë pre-sistemiese 
metabolisme, soos aangedui deur die hoë vlak van metaboliet wat gemeet is na die hidroliese 
van weefselmonsters met β-glukoronidase. Sewe ure na onttrekking was 44% van die totale 
residue in die lewer teenwoordig as biointakte salbutamol en 39% op 24 uur na onttrekking. 
In nier is 28% en 30% van ouer salbutamol as 'n persentasie van die totale salbutamol 
onderskeidelik by 7 uur en 24 uur na onttrekking aangetref. Spier het 47% ouer salbutamol as 
'n persentasie van totale salbutamol by 7 uur na onttrekking gehad. Die persentasie het gedaal 
na 17% na 24 uur onttrekking. In vet was 11% van die totale salbutamol teen 7 uur as ouer 
salbutamol teenwoordig en 14% 24 uur na onttrekking. 
Die teoretiese maksimum daaglikse inname van salbutamol vir mense, bereken uit die data 
van die lam residu studie, is minder as 10% (16.88 µg/dag) van die aanvaarbare daaglikse 
inname (ADI) (180 µg/dag vir ‘n volwasse mens). Diereweefsel uit voerkraal lammers wat 
volgens die etiketaanbevelings R-salbutamol gevoer word, met ‘n nul onttrekking in voer, sal 
dus sal voldoende beskerming van verbruikers bied . 
In 'n soortgelyke studie wat in beeste uitgevoer is, het een groep van vier beeste nie 
gemedikeerde voer ontvang nie en gedien as die negatiewe kontrolegroep. Drie groepe van 
ses beeste elk het vir 44 dae 150 mg R-salbutamol / kop / dag (0.42 mg/kg LM) in voer 
ontvang. Een dier van die kontrolegroep is op studie dag 3 geslag. Die drie medikasie groepe 
is geslag op onderskeidelik <12, 24 en 48 uur na die onttrekking van R-salbutamol uit voer, 
saam met een elk van die kontrolegroep. Die kontrole diere is ingesluit om aan te toon dat 
daar geen residue binne die toets kudde voorkom nie. Lewer-, nier-, spier- en vet monsters is 
versamel en ontleed vir salbutamol residue. Geen residue is opgespoor vir totale salbutamol 
(LOQ = 3 μg / kg) in enige van die weefsels nie. Geen visuele newe-effekte is waargeneem in 
die studie diere nie, en R-salbutamol was dus goed verdra in voerkraalbeeste. 
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Uit die data in hierdie studie word dit voorgestel dat die Maksimum Residu Vlak vir R-
salbutamol ingestel word vir lewer teen 300 μg / kg, spier teen 6.5 μg / kg, nier teen 40 μg / 
kg en vet teen 13 μg / kg. Op hierdie vlakke sal die daaglikse inname van residu steeds onder 
20% van die ADI wees. 
Verdere ondersoek na binneaarse en mondelingse farmakokinetika van R-salbutamol by 
beide beeste en lammers sal voordelig wees om die absorpsie, verspreiding, metabolisme en 
uitskeiding van R-salbutamol beter te verstaan in voerkraalbeeste en lammers. 
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 Background 
Livestock production is one of the major role players in agricultural economics, contributing to 
40% of the South African agricultural gross domestic product (GDP).  It employs 1.3 billion 
people and is the major source of livelihood for over a billion poor people (Steinfeld, et al., 
2006). 
Currently, meat contributes to one third of the protein intake of the world, but with an increase 
in population numbers to an estimated 9 billion in 2050 and income growth, food preferences 
are placing an increased demand on livestock production with a doubling in demand for meat 
predicted from 229 million tons in 1990/01 to a staggering 580 million tons in 2050 (UNPD, 
2007). This will also have a significant impact on the environment and technologies in 
agriculture will have to be developed and employed to reduce the impact of livestock 
production on the environment by half to decrease the already significant impact it has 
(Steinfeld, et al., 2006). 
On top of a growing demand for meat and pressure on reducing the environmental impact of 
increased livestock production, there is an ever-increasing competition between animals and 
humans for available land.  Hence significant improvement in production efficiencies is one of 
the major drivers to provide for the ever-increasing need for more meat. One major production 
system that is growing internationally is intensive production systems such as feedlots that 
have started becoming more common for ruminants. Currently, technologies including 
steroidal hormone implants, ionophores and beta-adrenergic agonists are available in certain 
countries and are utilised to improve production efficiency of livestock production in these 
intensive production systems.  However, more and more pressure from consumers is placed 
on the withdrawal of these products from livestock production systems, although the 
withdrawal of these products in the EU was “precautionary” in nature as authorities felt that it 
could not, with certainty, say that there was an absence of a health risk after performing risk 
assessments.  The ban was therefore due to consumer pressure rather than scientific facts 
(Kerr & Hobbs, 2005).  
Capper and Hayes (2012) studied the impact of the removal of growth enhancing technologies 
(GET) on the economy and environment in the United States.  The reduction in production 
Stellenbosch University  https://scholar.sun.ac.za
2 
efficiency with the withdrawal of GET would result in less meat being produced and would 
increase the required beef population size, to produce the 454 million kg meat shortfall, with 
385 000 animals.  Water consumption will increase with 20.14 x 106 litres, land use will 
increase by 265 000 ha and feedstuff consumption by 2.8 million tons.  Subsequently, the 
manure output will increase with 1.8 million tons leading to an increase in carbon emissions 
of 714.5 t/454 million kg beef produced. 
At the centre of the GET ban is the safety of the products in question and the need for scientific 
evaluation of the effect of such technologies on the health and safety of the consumer.   
Beta-adrenergic agonists (β-AA) (non-hormonal growth enhancers) have been used in beef 
production over the past 20 years and was first introduced into the South African market in 
1995 (Webb, Allen, & Morris, 2018). The first product registered was Zilmax (zilpaterol 
hydrochloride, MSD Animal Health). Following the introduction into the South African market, 
Zilmax has been registered in other countries including the United States (US), Canada and 
Mexico (Merck Animal Health, 2017).   
Paylean™ was the first β-AA to be introduced into the US market for use in pigs in 1999 (FDA, 
1999) and Optaflexx™ 45 (ractopamine hydrochloride, Elanco Animal Health) for use in beef 
cattle in 2003 (FDA, 2003). Ractopamine, as with all other beta-agonists, is banned for use in 
production animals for improved production efficiency in the EU (European Commision, 2005) 
and Mainland China (Meador & Wu, 2011), but has been determined safe by Regulatory 
Authorities in 27 countries, including the United States, Canada, Mexico, Japan, South Africa 
and South Korea. 
R-salbutamol, a β-AA, was introduced into the South African market in 2014 for use in beef 
feedlots for production improvement and in 2017 for use in sheep feedlots as Salbutamate 
10% by Animate Animal Health (43 Hornbill Road, Rooihuiskraal, Centurion, South Africa). 
Salbutamate 10% is the first β-AA to be registered for use in sheep feedlots in South Africa 
(Animate Animal Health, 2017).  The benefit of the use of R-salbutamol, above that of 
especially zilpaterol, is that it does not have a negative effect on the tenderness of beef and 
lamb (Dávila-Ramírez, et al., 2013; De Klerk, 2016; Du Toit, 2017; Steenekamp, 2014; Webb, 
Allen, & Morris, 2018). 
As part of the registration requirements for veterinary drugs used in production animals, of 
which the meat is intended for human consumption, residue studies in the target animals must 
be performed and these form part of this study (MCC, 2004; VICH, 2015). The aim of these 
investigations is to determine the levels of the marker residue, parent salbutamol, and total 
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salbutamol (parent + metabolite) in lambs and cattle treated with R-salbutamol during the 
feedlot finishing phase. An extensive safety risk assessment will also form part of this thesis 
to determine the Acceptable Daily Intake (ADI) for humans, which is the level of residues in 
animal tissue remaining after treatment, deemed safe for human consumption, and the 
subsequent determination of a Maximum Residue Limit (MRL) for R-salbutamol in lamb and 
cattle tissue (meat, liver, kidney and fat). 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Introduction 
Synthetic Beta-adrenergic agonists (β-AA) have been used for the treatment of asthma since 
the 1940’s (Konzett, 1940).  Since the development of the first synthetic β-AA, isoproterenol 
(isopropyl adrenaline), many new molecules have been investigated with varying degrees of 
efficacy and safety profiles. 
With the ban in Europe of hormonal growth promoters in 1986, research was initiated to 
develop non-steroidal growth promoters and the use of β-AA were investigated as an 
alternative (Kuipers, Noordam, van Dooren-Flipsen, Schilt, & Roos, 1998).  In the 1980’s 
research was done on various β-AA with regards to performance improvement, including 
salbutamol, ractopamine, cimaterol, L 664,969 and clenbuterol (Mersmann, 1998; Ricks, 
Dalrymple, Baker, & Ingle, 1984). 
2.2 History of Beta-Agonist development 
The development of β-AA as a treatment for asthma started at the end of the 19th century 
following the observations by the physician, George Oliver, that ingestion of a sheep’s adrenal 
gland caused radial artery constriction. Subsequent, research together with Edward Shafer 
confirmed a strong action of adrenal extract on the heart, blood vessels and skeletal muscles 
(Oliver & Shafer, 1895).  Takamine (1901) as referenced by Tattersfield (2006), was the first 
person able to extract the active ingredient from the adrenal gland and named it adrenalin in 
his 1901 publication.  It was subsequently marketed as Adrenalin by Parke, Davis & Company. 
Initially in the 1890’s, adrenalin was used for the treatment of asthma with little success, but 
Solomon Solis-Cohen (1900) persisted that it would work by increasing the dosage and so 
started the evolution of asthma treatments. In the early development of the use of adrenalin 
as asthma treatment it was noted that taking adrenalin via the oral route had little to no effect. 
By injecting adrenalin subcutaneously, or by inhaling adrenalin, it was later noted that some 
of the adverse events were reduced. 
So, the research into synthesised β-AA started in earnest.  The early research was focused 
on asthma in humans. In 1965, Cunningham presented the first data indicating that 
epinephrine and nicotine administration can lead to changes in pig growth (Cunningham, 
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1965). The first major commercial investigation was performed at American Cyanamid Co. in 
the early 1980’s with research into the effect of clenbuterol in cattle (Ricks, Dalrymple, Baker, 
& Ingle, 1984).  Subsequently, many other research projects were performed and reported on, 
with different β-agonists (e.g. salbutamol, ractopamine, cimaterol, L664,969) indicating 
variable responses in chickens, pigs, cattle and sheep (Mersmann, 1998). 
2.3 β-Adrenergic Receptors 
Cells have developed receptors to transmit signals from external stimuli into important 
physiological responses within the cell.  Beta-adrenergic receptors (β-AR) are one of many 
highly specialised receptors (Ostrowski, Kjelsberg, Caron, & Lefkowitz, 1992) and together 
with α-adrenergic receptors, form part of a group of G protein-coupled receptors (GPCR) 
(Johnson, Smith, & Chung, 2014). 
The existence of specific receptors on body cells that regulate either inhibiting or stimulatory 
responses within the body in reaction to the binding of neurotransmitters or drugs, were first 
described by John Newport Langley, a physiologist in Cambridge, during the late 1800’s 
(Langley, 1875; Maehle, 2004). Paul Ehrlich described these transmitters to be selective 
(Limbird, 2004). It is not until 1948, however, that the existence of alpha (α) and beta (β) 
adrenergic receptors was described by Ahlquist (1948) with both an inhibitory and excitatory 
effect caused by adrenalin. 
Alpha adrenergic receptors (α-AR) are found in the circulatory system on vascular smooth 
muscle and are responsible for controlling blood pressure. Two types of α-AR have been 
described, namely α1 and α2 (Reid, 1986).  For the purpose of the further discussion, focus 
will be on the β-AR. 
β-AR are present on the surface of almost every type of mammalian and avian cell which are 
targets for ligands, such as catecholamines, leading to various physiological processes when 
stimulated (Mersmann, 1998).  β-AR’s are glycoproteins within the membrane of certain types 
of cells within the body (De Blasi, 1989).  The three subtypes of β-AR are: 
 β1-AR,
 β2-AR,
 β3-AR.
The pharmacological and physiological responses of cells are determined by the specific ratio 
of these three β-AR subtypes present on that cell.  The distribution and proportion of the 3 
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sub-types of β-AR differ between tissues types as well as between species in a specific tissue 
type (Mersmann, 1998). The β2-AR is one of the most widely studied receptors (Ostrowski, 
Kjelsberg, Caron, & Lefkowitz, 1992) and the focus of this review. 
β -AR contain seven transmembrane domains which are hydrophobic in nature as illustrated 
in Figure 2.1. 
Figure 2.1: β-AR model (Johnson, Smith, & Chung, 2014) 
β-ARs are made up of more than 400 amino acids and similarities between β-receptors in their 
amino acid make-up is approximately 50%, whereas these similarities between species within 
a specific sup-type is approximately 75% (Mills & Mersmann, 1995).  
2.4 β-Adrenergic Agonists 
Agonists are defined as compounds that bind to receptors and have a similar or more potent 
effect than the natural occurring mediator (Fiems, 1987). The neurotransmitter, 
norepinephrine and the adrenal medullary hormone, epinephrine, are the natural occurring 
physiological adrenergic agonists (AA) responsible for stimulating β-AR (Fiems, 1987).  β-AA 
have a chemical similarity to ephedrine and nor-ephedrine in that they all share a basic 
chemical structure (Fiems, 1987). 
Oral administration of some β-AA lead to a production improvement due to increases in muscle 
and decreases in fat accretion in cattle, pigs, poultry, and sheep. The exact mechanism of 
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action is not yet fully understood due to the complex nature of the functions controlled by β-
AA (Mersmann, 1998).  
The first possibility is that of the direct effect within fat and muscle cells (Mersmann, 1998). 
Other mechanisms should however also be considered such as the effect of the central 
nervous system on feed intake (Ordway, O’Donnell & Frazer, 1987), increased blood flow 
(Beermann, et al., 1987; Eisemann, Huntington, & Ferrell, 1988; Mersmann, 1989) to target 
organs and hormonal release (Beermann, et al., 1987). Specific focus should also be placed 
on the pharmacodynamic properties of individual molecules within the class of β-AA and the 
different effects that they may have between species as well as within species at different 
physiological ages and the effect of different diets thereupon (Mersmann, 1998). 
Variability in the effect of different β-AA in different species could be attributed to different 
factors according to Mersmann (1998), which included the difference in agonistic effect 
between molecules in a specie due to the affinity of an agonist to the receptor, and/or the 
delivery mode of the agonist to the target tissue. β-AR may also be inactivated more rapidly 
by certain β-AA and some β-AA may have a higher affinity for certain β-AR sub-types.  Specie 
differences in amount of β-AR on a specific target tissue may also lead to a difference in 
response. 
2.4.1 Mode of action of β-AA 
When a phenethanolamine or β-AA binds to the Beta-AR on the extracellular N-terminus of 
the receptor, the receptor is stimulated, and a conformational change is activated in the β-AR. 
This in turn allows for the binding of the GS-protein (guanine nucleotide simulating protein) to 
the intracellular loop of the receptor.  The GS-protein coupling activates adenylyl cyclase (AC) 
which transforms ATP (adenosine triphosphate) to cAMP (cyclic adenosine monophosphate). 
The increasing cAMP stimulates the phosphorylation of protein kinase A (PKA to pPKA) (De 
Blasi, 1989; Ostrowski, Kjelsberg, Caron, & Lefkowitz, 1992; Johnson, Smith, & Chung, 2014; 
Mersmann, 1998). 
Depending on the specific tissue where the β-AR stimulation takes place the formation of 
pPKA will trigger different physiological processes (Figure 2.2).   
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Figure 2.2: β-AR mechanism of action (Anderson, Moody, & Hancock, 2009) 
In fat cells, the formation of pPKA stimulates the hydrolysis of triacylglycerol (TAG) through 
the activation of adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) which 
leads to increased lipolysis (Ricks, Dalrymple, Baker, & Ingle, 1984; Johnson, Smith, & Chung, 
2014; Mersmann, 1998). 
In muscle cells, the increased levels of cAMP leads to the phosphorylation of adenosine 
monophosphates-activated protein kinase (AMPK) which in turn is positively correlated with 
an increase in mRNA levels in muscle fibers and involved in energy metabolism (Johnson, 
Smith, & Chung, 2014; Lynch & Ryall, 2008).  Numerous studies have indicated that the 
increased muscle mass is due to increased mRNA levels in muscle in contrast to an increase 
in DNA as in the case of steroid hormone treatment (Walker, et al., 2010). 
Contradicting work has been reported with regards to the reason for the increased muscle 
mass, with some researchers reporting an increase in protein accretion, some a decrease in 
protein degradation and in some instances, both. This seems to be specific to the animal 
species investigated and the type of β-AA used in the trials performed (Fiems, 1987; Moody, 
Hancock, & Anderson, 2000). 
Protein accretion, and subsequent muscle growth, is associated with a change in the activity 
of calpastatin and calpains within the muscle of β-AA treated animals. An increase in calpain 
I activity was observed at low growth rates in non-responsive muscle types, but a decrease 
was reported at higher growth rates.  As growth however increased, an increase in calpastatin 
and calpain II activity was observed (Bardsley, et al., 1992). 
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2.4.2 Differences in physiological activity of the different β-AA’s 
The physiological activity of β-AA is determined by the activity of the molecule at the receptor 
as well as how it is absorbed, the rate of metabolism and elimination and subsequent 
distribution to the target tissues.  The chemical characteristic of the β-AA may also influence 
these parameters.  Therefore, it is important to determine and investigate the pharmacokinetic 
properties of each of the β-AA molecules to determine the specific effect and subsequent 
toxicity of the molecule within the broader group of β-AA (Smith, 1998).   
As in the case of steroid hormones, the physiological function and activity of a class of 
molecules cannot be over generalized.  For example, estrogen, aldosterone and testosterone 
are all steroid hormones with similar chemical properties, they have very different physiological 
functions. Similarly, different β-AA differ in their physiological activity (Smith, 1998).  
The biological activity of β-AA is determined by the aromatic ring attached to the β-carbon 
(Figure 2.3). Various substitutes are attached to the aromatic ring which in turn determines 
the half-life, route of metabolism as well as the efficacy of the molecule at receptor level. The 
structure of chemically synthesised β-AA is similar to the natural occurring adrenergic 
neurotransmitters norepinephrine and epinephrine except for the bulky group on the R-group 
of the aliphatic nitrogen (Figure 2.3) (Smith, 1998). 
Aromatic Substitution 
A B C Category Example(s) 
-H -OH -H Phenol Ractopamine 
Ritodrine 
-OH -H -OH Resorcinol Fenoterol 
Terbutaline 
-OH -OH -H Catechol Isoproterenol 
Dobutamine 
-CH2OH -OH -H Saligenin Salbutamol 
Salmeterol 
Figure 2.3: General structure of β-AA and common substitutions on the aromatic rings. The R-group is 
a bulky group on the aliphatic nitrogen, usually an isopropyl, alkylphenol, alkylphenyl or t-butyl group.  
Labels p- and m- on the aromatic ring indicate the para- and meta- position relative to the beta-carbon 
(Smith, The pharmacokinetics, metabolism, and tissue residues of beta-adrenergic agonists in 
livestock, 1998). 
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Smith (1998) explained the intricate differences with regards to the chemical structures and 
subsequent efficacy of the different available β-AA in detail.  In summary, the substitution at 
the β-carbon influences the longevity of the activity of a β-AA at the receptor in mammalian 
and avian species. β-AA with a 3-hydroxyl group on the aromatic ring (catechols) are 
metabolised at a very rapid rate by catecholamine O-methyl transferases (COMT) leading to 
limited effectiveness if dosed via the oral route.   
The route of metabolism is also influenced by the nature of the substitution on the aromatic 
ring.  β-AA were developed with different patterns of hydroxylation (grouped as the phenols, 
resorcinols and saligenins) to retain activity at the β-AR which are not affected by COMT but 
are rapidly metabolised in the liver and intestinal wall leading to a short half-life. These 
molecules include ractopamine and salbutamol (Smith, 1998). 
Subsequently, new β-AA were developed that were still active at binding the β-AR but are 
more resistant to metabolism. These beta-agonists have halogen substitutions in the place of 
hydroxyl groups. These include molecules such as clenbuterol, cimaterol and mabuterol, 
salbutamol, ractopamine and zilpaterol (Morgan, 1990; Anderson, Moody, & Hancock, 2009).  
The differences in molecular structure for these β-AA are indicated below in Figure 2.4. 
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Figure 2.4: Molecular structure of some phenethanolamines. β-AR affinity is indicated in parentheses 
(Anderson, Moody, & Hancock, 2009). 
Lipophilicity is also influence by the hydrogen substitution on the aromatic portion.  As an 
example, salbutamol has a much lower lipophilicity than salmeterol, which is lipid-soluble.  The 
length of the N-arylalkyloxyalkyl side chain differs dramatically between the two molecules 
with that of salmeterol being much longer than the side chain of salbutamol.  The side chain 
of salmeterol has an affinity for the cell membrane in contrast with that of salbutamol which is 
too short to bind to the cell membrane.  Therefore, salbutamol remains extracellular (Smith, 
1998).   
The β-carbon determines the chirality of the molecule, determining the dextrorotatory and 
levorotatory stereoisomers (Smith, 1998).   
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2.4.3 Enantio selectivity of β-AA with specific reference to salbutamol 
Ruffolo (1991) indicated that the levorotatory stereoisomer is solely responsible for the 
biological activity of direct-acting β-AA. 
Stereoisomers are structurally identical molecules with the only difference that the one is a 
mirror image of the other.  The isomers for salbutamol are shown in Figure 2.5. 
S-salbutamol R-Salbutamol 
Figure 2.5: The S- and R-isomers for salbutamol (iKnowledge, 2015). 
Research has indicated that racemic β-AA can cause airway hyper-reactivity in humans and 
animals and that this could be a secondary cause to β-AR desensitisation. The hyper-reactivity 
is indicated to be caused by the S-enantiomer of β-AA.  The more active R-enantiomer is 
referred to as the eutomer and the less active S-enantiomer, the distomer (Waldeck, 1999).  
Salbutamol is a rapidly-acting, potent non-catecholamine β2 selective agonist. It binds 
reversibly to β2-AR which are located in several sites in the body, such as airway smooth 
muscle cells (causing relaxation), mast cells (inhibiting histamine release) (Russo et al., 2005) 
and elsewhere e.g. uterus (causing contractility), cardiovascular system (causing palpitations) 
and voluntary muscle (leading to tremors) (Anon, 1971; Health Products Regulatory Authority, 
1983; Libretto, 1993).   
The binding sites of interest for the application of R-salbutamol in production animals are 
adipose and lean muscle cells where binding results in repartitioning (Sumano, Ocampo, & 
Guteirrez, 2002). 
It has been found that the desired bronchodilatory effect of salbutamol is a consequence of 
β2-AR stimulation by R-salbutamol (Hartley & Middlemiss, 1971). Similarly, the 
bronchodilatory effect of the β-AA, terbutaline (used as a bronchodilator in humans) was also 
found to be due to the R-enantiomer (Wetterlin, 1972). 
S-salbutamol has virtually no affinity for β2-AR and as such no therapeutic activity in this 
context (Fawcett, et al., 2004).  The side effects of racemic salbutamol administration are 
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commonly manifestations of β2-AR stimulation: for example, fine muscle tremor, flushing, 
palpitations and sometimes tachycardia. S-salbutamol has no bronchodilating activity and has 
detrimental effects on airways, such as pro-inflammatory actions and may mask the desired 
bronchodilatory effects of the R-isomer when administered as part of a racemic mixture 
(Hansen, Yen, Klindt, Nelssen, & Goodband, 1997). It follows that a derivative of racemic 
salbutamol which is optically pure for the R-isomer would have superior activity with reduced 
side effects due to the absence of S-isomer interference. 
R-salbutamol is more potent than an equivalent dose of racemic salbutamol (Hansen, Yen, 
Klindt, Nelssen, & Goodband, 1997). The Xopenex FDA approved label (Sepracor Inc., 1999) 
stated that “R-salbutamol has a 2-fold greater affinity for beta receptors than racemic 
salbutamol and a 100-fold greater affinity than S-salbutamol”. Thus, in isolation, R-salbutamol 
has a greater potency (without the competitive inhibition by the S-salbutamol for the receptor 
sites) and greater pharmacodynamic effects. This was also found to be the case with R-
terbutaline having a 1000-fold more potent effect than S-terbutaline (Jeppsson, Johansson, & 
Waldeck, 1984). R;R-fomoterol was also found to be 1000-fold more potent than S;S-fomoterol 
and R;R-fomoterol also had an increased effect on the beat frequency of cilia in the tracheal 
mucosa with S;S-formoterol having no effect (Lindberg, Khan, & Runer, 1995).  The same 
potency difference was observed between R-clenbuterol and S-clenbuterol (Waldeck & 
Widmark, 1985).  
The improved efficacy of R-salbutamol in the absence of S-salbutamol has led to the 
development of Salbutamate 10% for use in animal production. The presence of only the R-
isomer enables producers to only dose half of what the therapeutic dosage would have been 
for the racemic formulation. Fawcett et al. (2004) observed similar production improvements 
in chickens fed racemic salbutamol at 10 ppm vs. R-salbutamol at 5 ppm in feed. The chickens 
fed 10 ppm racemic salbutamol had higher tissue concentrations of salbutamol compared to 
the chickens fed 5 ppm and 10 ppm R-salbutamol (Table 2.1). 
 Table 2.1:  Influence of diets containing R-salbutamol and racemic salbutamol on concentration of 
salbutamol residues in tissues of 42-day old chickens (Fawcett et al., 2004) 
Diet Concentration in tissue (mg/kg) 
Plasma Liver Fat Muscle 
5 ppm R-salbutamol  7.6 ± 0.8 34.1 ± 4.9 5.7 ± 1.1 11.7 ± 1.2 
10 ppm R-salbutamol 14.5 ± 2.7 65.5 ± 11.4 6.2 ± 1.2 21.8 ± 3.6 
10 ppm Racemic Salbutamol 23.1 ± 2.5 173.2 ± 8.65 14.8 ± 0.3 29.8 ± 1.85 
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The reduction in the total dosage of R-salbutamol in comparison to racemic salbutamol 
therefore has the potential benefit for reduced residue levels in the tissue of treated animals.  
2.4.4 Absorption, distribution, metabolism and excretion of β-AA 
The half-life (t½) of a substance is the time it takes for a substance to lose half of its 
pharmacological or physiological effect (Riviere, 2009).  
Two classes of β-AA are found. Those with halogenated aromatic ring systems and those with 
hydroxylated aromatic ring systems. In general, the β-AA with halogenated aromatic ring 
systems are metabolized via conjugative oxidative pathways and subsequent longer plasma 
half-lives. β-AA with hydroxylated aromatic rings are only metabolized by conjugation and 
subsequently have short plasma half-lives (Smith, 1998).  
β-AA with high oral bioavailability, long plasma half-lives, and relatively slow rates of 
elimination lead to high oral potencies in humans consuming animal tissue treated with β-AA 
(hereto further referred to as consumers). On the other hand, the β-AA with low oral 
bioavailability, short plasma half-lives, and rapid rates of elimination have low oral potencies 
in consumers as the shorter plasma half-life leads to much lower residues in edible tissue and 
a much lower risk to consumers (Smith, 1998). 
Various studies have investigated the extent of absorption in humans and animals of various 
β-AA by monitoring the plasma levels after single exposure and long-term exposure to variable 
dosage levels. Most β-AA achieve peak plasma levels within 1 to 3 hours following oral 
administration in humans and animals (Morgan, 1990; Meyer & Rinke, 1991). Peak plasma 
levels of clenbuterol in calves were observed to increase with repeated dosing indicating 
accumulation of clenbuterol (Sauer, Limer, & Dixon, 1995). Similar peak plasma levels as with 
clenbuterol were observed when salbutamol was orally dosed in cattle, although the oral dose 
of salbutamol was several times higher than that of the oral clenbuterol dosage.  No increase 
in plasma peak levels was observed after multi day dosing of salbutamol, indicating that 
salbutamol does not accumulate as in the case of clenbuterol (Pou, et al., 1992).   
The extent of drug absorption should also be evaluated based on the extent of urinary 
excretion and not only be based on the plasma levels obtained.  Radio-labelled clenbuterol 
was rapidly absorbed within an hour in calves following oral dosage and recovery in urine and 
the non-gastrointestinal components accounted for 76% of the radiolabel although less than 
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50% were excreted in the urine after 48 hours (Smith & Paulson, 1997).  In contrast, in swine 
more than 88% of radiolabelled ractopamine HCl were excreted in the urine (Dalidowicz, 
Thomson, & Babbitt, 1992). 
Although radiolabelled salbutamol studies have not been performed in food producing animals 
to the knowledge of the author, studies have been performed in rats, rabbits, dogs and 
humans.  Sixty percent of radiolabelled salbutamol were absorbed by rats, 90% in humans 
and 65% in dogs.  Differences between species were however observed in the amount of free 
salbutamol excreted in urine.  Dogs excreted the majority (60 – 90%) of salbutamol in the free 
form, whereas 60% were excreted as free salbutamol and 40% as a glucuronide conjugate in 
rats within 24 hours. The glucuronide is formed mainly in the liver (Martin, Hobson, Page, & 
Harris, 1971).   
Like all drugs, the extent of salbutamol systemic absorption depends upon the route of 
administration. 
For asthma treatment in humans, the usual route of drug delivery is via inhalation or nebuliser. 
Research has shown that a portion of the drug will be swallowed when administered this way 
providing more data on the drug's fate after oral absorption (Ward & Schultz, 1995). 
Salbutamol is rapidly absorbed after oral administration with most of the dose being excreted 
in urine as parent or metabolite in humans (80-100% over 24 hours). Almost complete 
absorption occurs when given extravascular in humans (Boulton and Fawcett, 2001).  Ward 
et.al (2000) reports the slow oral absorption of R- and S-salbutamol after oral dosing (2 - 3 
hours to peak) compared with a peak plasma concentration of 1 - 4 hours in racemic studies. 
Notably, S-salbutamol takes longer (tmax) to reach maximum plasma concentration (Cmax) than 
when administered as part of the racemate (Price & Clissold, 1987; Ward, et al., 2000). 
In one study, the bio-availability of R, S-salbutamol (as a mean of both enantiomers) following 
an oral dose was 39% compared to 42% as an inhaled dose. But, the bioavailability of pure 
R-salbutamol was lower following an oral dose (9%) than an inhaled dose (24%) (Ward, et al., 
2000). The reduced bio-availability of R-salbutamol is thought to be due to competitive 
inhibition of metabolism by S-salbutamol and highlights the differences that exist when 
comparing chiral and non-chiral studies (Boulton & Fawcett, 1997). 
Absorption is not the limiting factor for pharmacological activity of β-AA, but rather the rate of 
biotransformation and excretion is (Smith, 1998). Several researchers mention that R-
salbutamol is subject to intestinal pre-systemic metabolism in the gut wall of humans by a yet 
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to be identified enzyme that does not exist in livestock animals, significantly affecting 
bioavailability in humans (Boulton & Fawcett, 1996a; Ward, et al., 2000) 
Enantiomer inter-conversion also occurs in the gut probably due to acid-catalysed 
racemisation in the stomach, resulting in an insignificant inversion to the S-isomer after oral 
administration of pure R-salbutamol (Boulton & Fawcett, 1996a; Ward, et al., 2000).  Later, 
Fawcett et al. (2004) reported that chickens on diets containing R-salbutamol gave rise to the 
drug in tissue with no evidence of racemisation. 
Intravenous studies in rats show that racemic salbutamol crosses the blood-brain barrier thus 
explaining some of its central nervous systematic effects at high doses (Price & Clissold, 
1987). 
There is rapid absorption and distribution of salbutamol in humans. Plasma protein binding is 
not significant for either enantiomer and is dose dependant, ranging from 7 - 64% and the 
blood:plasma ratio is  ̴1 (Boulton & Fawcett, 2001). Tissue binding is not enantio-selective 
(steady state volumes of distribution are alike). Salbutamol has a prolonged distribution phase 
of longer than 2 hours (Boulton & Fawcett, 2001). The apparent volume of distribution in 
humans is 156L after intravenous administration (Price & Clissold, 1987) indicating extensive 
extra vascular uptake/distribution. 
Most β-AA are metabolised by conjugation to form a major metabolite (i.e. they are 
uncomplicated by multiple metabolic pathways). This is also true for the metabolism of 
salbutamol and its enantiomers. But unlike other β2-AA, R-salbutamol ("active" enantiomer) 
is metabolised faster than S-salbutamol (the "inactive" enantiomer) leaving a disproportionate 
amount of S-salbutamol in the system relative to the dose of parent drug (Boulton & Fawcett, 
1996b; Ward & Schultz, 1995). 
The metabolism of salbutamol differs in humans and animals. Sulphated conjugates (4'O-
sulphate) are the main metabolites in humans, whilst glucuronic acid conjugates (4'O-
glucuronide) are the main metabolites in rodents (rats and rabbits) and dogs (Boulton & 
Fawcett, 1996a; Walle, Pesola, & Walle, 1993). Furthermore, there is a marked interspecies 
variation in the extent of glucuronidation. For example, in dogs 30% and in rabbits 90%, of 
total urinary radioactivity has been recovered as glucuronide conjugate (Boulton & Fawcett, 
1996a).  This complicates comparative studies between different species. The conjugation 
salbutamol at the p-hydroxyl group renders salbutamol with no metabolic activity. Therefore, 
the metabolite is physiologically inactive (Martin, Hobson, Page, & Harris, 1971).  
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It is worth noting that whilst the comparison of salbutamol metabolism in humans and in 
animals is not simple and direct, the clinical relevance of the differences has not been 
demonstrated. In humans, sulphate conjugation is catalysed by a highly stereo-selective 
monoamine form of phenolsulphotransferase. Research has demonstrated that salbutamol 
metabolism is indeed stereo-selective, with the two enantiomers competing for enzyme 
occupancy (Ward, et al., 2000). In chickens, the metabolism of racemic salbutamol is stereo-
selective, with the two enantiomers competing for the enzymes of metabolism and exhibiting 
the same pattern observed in humans (Fawcett, et al., 2004). In contrast, Ward et al (2000) 
found that enantio-selective metabolism did not occur in the lungs and was confined to the 
gastrointestinal tract (GIT) and systemic circulation in humans. Nevertheless, there will be 
overexposure to S-salbutamol after intravenous and oral administration (the latter due to the 
extensive presystemic GIT metabolism in humans). 
Sulphoconjugation occurs in the small intestine (presystemic) and in the liver (first-pass) in 
humans. Presystemic intestinal metabolism is the major route of elimination following oral 
administration in humans. The sulphate conjugate has no pharmacological activity (Boulton & 
Fawcett, 1996b; Ward, et al., 2000). 
Hepatic metabolism accounts for around half the clearance of R-salbutamol from plasma, such 
that the plasma concentration of S-salbutamol at steady state during intravenous infusion of 
the racemate should be ±1.5 times greater than R-salbutamol. Oral administration gives the 
highest difference in enantiomer plasma concentration (due to the presystemic gut 
metabolism). There is a reported 2.4-fold difference at steady state and 7.3-fold difference 
after a single oral dose (Boulton & Fawcett, 2001). In humans, the plasma concentration of 
the sulphate conjugate is around five times that of salbutamol, 1 - 5 hours after oral or 
inhalation dosing. The metabolite is virtually undetectable after intravenous administration 
(Price & Clissold, 1987). Studies show a 5 - 11-fold greater sulphoconjugation of R-salbutamol 
in different human tissues. The resulting blood levels of salbutamol consist predominantly of 
the inactive S-salbutamol, at least partially explaining why dose-response curves from 
salbutamol blood levels have never been successfully determined (Pesola & D'Costa, 2004). 
There is thought to be a large enantiomeric selective first-pass effect after oral administration 
such that R-salbutamol is less bio-available than S-salbutamol (30% vs. -70%) (Boulton & 
Fawcett, 1997). Due to the selectivity of metabolism and excretion, S-salbutamol will 
predominate systemically. 
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Regardless of the route of administration, salbutamol and its metabolites are rapidly excreted 
in urine and faeces. The excretion of parent and metabolised salbutamol could potentially 
have an impact on environmental contamination.  Steenekamp (2014) reported ten times lower 
levels of salbutamol residues excretion in faeces in comparison to zilpaterol when fed to cattle. 
The residues declined rapidly in faeces following a 3-day withdrawal period (Figure 2.6). 
Figure 2.6: Zilpaterol and R-salbutamol residues in cattle faeces (Steenekamp, 2014) 
Zhou (2017) found salbutamol to be sensitive to photo degradation and residues will 
subsequently not build up in the environment due to degradation by ultraviolet light.  
An Italian study (Zucatto, et al., 2006) measured levels of pharmaceuticals in two rivers. 
Predicted environmental concentrations were calculated based on prescription figures and 
theoretically adjusted for the percentage of each drug excreted as a parent compound. The 
ratio of measured to predicted environmental concentrations of salbutamol was 0.12 in one 
river and 1.96 in the other. The detected levels were very low (1 – 8 ng/L) in comparison to 
other detected pharmaceuticals. Ofloxacin were detected at levels between 33 and 600 ng/L. 
Based on predicted environmental concentrations of salbutamol it was concluded that 
salbutamol was not a threat to the environment. 
On a cellular level, it is believed that organic cation transporters are responsible for eliminating 
salbutamol and metabolites from cells (Boulton & Fawcett, 2001). Around 80% of a single oral 
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dose was recovered from urine in 24 hours and around 30% was the unchanged drug (Boulton 
& Fawcett, 1996b). This is comparable to the findings in intravenous excretion patterns where 
75% of the dose was recovered in the urine (after 24 hours), 65% unchanged and 10% were 
metabolites (Price & Clissold, 1987). The different excretion pattern of unchanged drug in 
oral/inhalation and intravenous routes is probably due to the presystemic metabolism that 
occurs in the human gastrointestinal tract (Boulton & Fawcett, 1996b). 
Unchanged salbutamol undergoes active tubular secretion (clearance is greater than 
creatinine). The renal clearance of the metabolite is less than parent salbutamol which may 
indicate that it is freely filtered i.e. not actively secreted (Price & Clissold, 1987). 
According to Ward et al (2000), the half-life for the R-metabolite is shorter than the S-
metabolite and similar to the parent clearance rate. Since the metabolic clearance of S-
salbutamol is slower than that of R-salbutamol, accumulation of S-salbutamol will occur, 
resulting in a longer half-life for S-salbutamol compared to R-salbutamol. Terminal half-life 
was reported as 2.5 hours for R-salbutamol and 5 hours for S-salbutamol (Ward, et al., 2000). 
It is likely that the only stereo-selective renal clearance is active rather than selective tissue or 
plasma protein binding. 
Typically, data for elimination half-life depends on several variables. For example, the dosage, 
route of administration, health of the study subjects and whether the value is calculated from 
urinary data.  Price and Clissold (1987) reported that the elimination half-life of salbutamol in 
humans can range from 2.4 hours (intravenous) to 6.5 hours (for multiple oral doses). In 
contrast, another study found that in humans, the elimination rate of the 4'-O-sulphate 
metabolite is similar to the unchanged salbutamol after oral administration of the drug to 
healthy volunteers (Boulton & Fawcett, 2001). This suggested that the kinetics of elimination 
of the sulphate metabolite is formation rate limited. It is excreted shortly after it is formed due 
to its high polarity as shown by low plasma concentration and high recovery in urine (Boulton 
& Fawcett, 2001). 
In rats and dogs, radio labelled salbutamol is rapidly cleared from all tissues. The liver and 
kidney are the only organs in which small amounts of radioactivity are detected 24 hours after 
oral administration (Pesola & D'Costa, 2004). 
2.5 Human safety of β-AA use in production animals 
Stellenbosch University  https://scholar.sun.ac.za
21 
The Organisation for Economic Co-operation and Development (OECD) guidelines for pre-
clinical toxicological testing is based on internationally agreed testing methods to access the 
safety of chemicals. These guidelines have been adopted by the International Cooperation on 
Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products 
(VICH)  in the guideline  for evaluation of the safety of residues remaining in production 
animals following the administration of veterinary drugs (Guideline #GL33).  This guideline 
was developed by an expert working group consisting of representatives from regulatory 
bodies from Japan, United States of America (USA) and the European Union (EU).  The South 
African Department of Agriculture, Forestry and Fisheries (DAFF) is an observer to the 
steering committee and encourages the use of the VICH guidelines (VICH, 2018).  
These guidelines for the evaluation of the toxicology of veterinary drugs are in line with the 
guidelines for toxicological testing for pesticides, food additives and human medicine as set 
out by the OECD. The aim of the toxicological testing is to identify the no-observed adverse 
effect level (NOAEL) for the veterinary drug in question. The NOAEL can be defined as the 
“the highest experimental point that is without adverse effect” according to Dorato (2005). The 
lowest-observed adverse effect level (LOAEL) is therefore the lowest experimental point in a 
toxicological trial where an adverse effect is observed. 
There is however no standard definition of what is viewed to be an adverse effect and the 
interpretation of whether an effect observed is potentially harmful to humans, lies with the 
toxicologist (Dorato & Engelhardt, 2005). This review will therefore take the interpretation of 
the researcher and other reviewers of the experimental work as guidance in determining the 
NOAEL for the specific toxicological study.   
Depending on the veterinary drug in question, repeat dose studies, carcinogenic studies, 
reproductive toxicity studies, foetal developmental toxicity studies (teratology) and 
genotoxicity studies are evaluated as the basis of the safety evaluation to address the issue 
of “appreciable risk”. Additional studies, including neurotoxicity, immunotoxicity, 
pharmacological effects and the effect on human intestinal microflora can also be included 
based on the nature of the pharmaceutical in question.  In the case of antibiotics used as 
veterinary pharmaceuticals, the effect of residues in animal tissue on human intestinal 
microflora would be a very important factor to determine the toxicology of the antibiotic in 
question (VICH, 2009).  Due to the nature of β-AA, the toxicological studies of importance are 
as follows: 
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 repeat dose studies
 carcinogenic studies
 reproductive toxicity studies
 foetal developmental toxicity studies (teratology)
 genotoxicity studies
From each of these studies (performed at multiple dosage levels much higher than the 
anticipated routine dosage levels) the NOAEL is derived.   
The aim of evaluation within the toxicological studies is to determine the safety of any residues 
ingested by humans due to the application of any veterinary drug in food producing animals 
and therefore the preferred route of application is oral administration in any in vivo toxicological 
study evaluated. For each specific toxicological investigation, preferred target species are 
identified (VICH, 2009). 
The European Food Safety Authority (EFSA) undertakes amongst other things, safety 
evaluation for pesticides and other active substances based on requests for scientific advice 
from the European Commission (EC), European Member States and the European 
parliament.  This work is undertaken by appointed Scientific Committees and Scientific Panels 
(EFSA, 2018). The Panel on Additives and Products or Substances used in Animal Feed 
(FEEDAP) is responsible for evaluating the safety and/or efficacy of any additives used in 
animal feed. EFSA has done safety evaluations for two β-AA; zilpaterol and ractopamine 
(EFSA, 2009; EFSA, 2016).  
Similarly, the Joint FAO/WHA Expert Committee on Food Additives (JECFA), consisting of 
expert scientific committees that perform risk assessments on food additive safety, has 
evaluated the safety and completed the risk assessments on ractopamine, zilpaterol and 
clenbuterol (JECFA, 2018). EFSA uses the risk assessments performed by JECFA when 
undertaking their safety evaluations. 
A risk assessment has not been done for R-salbutamol use, as South Africa is the first country 
in the world to register the active ingredient for use in production animals. The aim of the 
following summary is to evaluate the safety and to do the risk assessment for R-salbutamol. 
2.6 Setting of an Acceptable Daily Intake (ADI) or Acute Reference Dose (ARfD) 
The end point of evaluating the toxicology of veterinary drugs is to determine the Acceptable 
Daily Intake (ADI) for the veterinary drug investigated. The ADI is then again used together 
Stellenbosch University  https://scholar.sun.ac.za
23 
with the animal tissue residue data derived from residue depletion studies to determine the 
Maximum Residue Limit (MRL) in new investigational veterinary drugs. The ADI together with 
the MRL and the residue depletion data is used to determine the Withdrawal Period (WP) (also 
referred to as the Withholding Period), at which point the consumption of any animal tissue 
derived from animals fed the veterinary drug is safe for human consumption (MCC, 2004). 
The ADI is defined by JECFA as “An estimate of the amount of a substance in food or drinking 
water, expressed on a body weight basis that can be ingested daily over a lifetime without 
appreciable risk (standard human = 60 kg BWt)”. This calculation would therefore only take 
the NOAEL values of the repeat dose studies, carcinogenicity, genotoxicity, reproductive and 
foetal toxicity studies into account. 
JECFA considered that certain drug classes may have more acute effects (pharmacological 
or toxicological) due to residue intake (usually in one meal) and that the sub-acute and long-
term studies used to determine the ADI may not be an accurate benchmark for toxicological 
evaluation. Therefore, depending on the nature of the compound in question, it may be of 
value to define an Acute Reference Dose (ARfD) from acute intake studies for certain 
compounds (JECFA, 2009).    
The ARfD is only relevant when the calculated acute effect is lower than the ADI determined 
for the veterinary drug in question and where the ARfD of the veterinary drug in question is 
below 1 mg/kg BWt in humans (JECFA, 2016). 
β-AA are known to have acute effects by increasing heart rate in humans and animals.  These 
effects in humans and animals are however dose related and differ between the different 
molecules within the class.  Fenoterol has been reported to have a more pronounced effect 
on the increase in heart rate than salbutamol or terbutaline and the effect on the increase in 
heart rate was dose related (Wong, Pavord, Williams, & al., 1990).  
It would also appear that a tolerance develops rapidly to the effect of β2-AA on the 
cardiovascular stimulating effect. Tachycardia is therefore only observed in infrequent users 
of β2-AA (Bremner, Woodman, Burgess, & et.al., 1993; Wong, Pavord, Williams, & al., 1990). 
Clenbuterol was one of the first β-AA to be investigated for use in animal production in the 
1990’s. American Cyanamid Company abandoned the development of clenbuterol as a 
productivity enhancer due to the residue toxicity in beef edible tissue (Johnson, Smith, & 
Chung, 2014). 
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Producers illegally using non-registered β-AA usually do so at higher levels than that tested in 
research trials and/or do not adhere to any withdrawal period that would deem the animal 
tissue produced safe.  The incorrect use of these β-AA can be attributed to ignorance 
regarding the application of these molecules or the believe that higher inclusion levels would 
increase production efficiencies. This would lead to residue levels in especially the liver and 
kidney (of the animals produced) that could lead to adverse effects in humans consuming such 
animal tissue (food poisoning) (Johnson, Smith, & Chung, 2014). 
In 1992 in Catalonia, Spain, 113 cases of clenbuterol food poisoning in humans related to the 
consumption of veal liver, from illegally fed clenbuterol to cattle, were reported. Of the 113 
cases, 50% of the affected individuals presented with symptoms of tachycardia, nervousness, 
headaches, and myalgia and muscle tremors. Symptoms presented between 15 minutes to 6 
hours after the ingestion of the liver and lasted between 90 minutes to 6 days (Salleras, 
Dominquez, Taberner, Moro, & Salva, 1995). In fact, between 1998 and 2002, 50 cases in 
four separate incidences of clenbuterol intoxication were reported in Portugal due to ingestion 
of lamb meat and beef meat and liver from animals fed clenbuterol, with symptoms ranging 
from tachycardia, distal tremors, nausea, epigastralgia, diarrhoea, fever, headaches and 
dizziness, myalgia and asthenia, hypertension, dry mouth and vomiting (Barbosa, et al., 2005).  
Many additional cases of acute clenbuterol food poisoning have been reported in France 
(Pulce, Lamaison, Keck, Bostvironnois, & Nicolas, 1991), Italy (Brambilla, et al., 1997; Maistro, 
Chiesa, Angeletti, & Brambilla, 1995) and China (Shiu & Chong, 2001) due to illegally fed 
clenbuterol in food production animals. 
Based on these observations, β-AA residues in animal tissue are more likely to lead to acute 
effects in humans when ingesting animal tissue and therefore the ARfD for R-salbutamol 
together with the ADI need to be evaluated to determine the safety of R-salbutamol to humans. 
The NOAEL is determined from the studies as discussed in section 2.7 and the lowest NOAEL 
value identified is used for the calculation of the ADI. It could then be summarised that the ADI 
is calculated to set a safe intake level in humans with regards to any long-term or chronic 
effects that a veterinary drug may have (VICH, 2009), whereas the ARfD is calculated to set 
a safe intake level in humans to prevent any acute effects that may arise from ingestion of 
residues via animal tissue derived from treated animals with the veterinary drug in question 
(JECFA, 2016). 
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2.7 Toxicity data on β-AA with specific focus on R-salbutamol and/or salbutamol 
2.7.1 Repeat dose studies 
Repeat dose studies are performed to determine the effect of repeated exposure (usually 
daily) at multiple levels expressed as mg/kg BWt to determine the effect of a veterinary drug 
and/or its metabolites after prolonged exposure and subsequently deriving a NOAEL (VICH, 
2004a).  According to the FDA and EU guidelines, only studies in rats are required, but in 
Japan studies in rodent and non-rodent species are required, with the rat as the accepted 
rodent species and the dog the accepted non-rodent species.  Selection of the target species 
should however be evaluated in terms of the relevance of the human pharmacokinetics, 
pharmacodynamics and metabolism of the veterinary drug in question (VICH, 2004a; b).  
Rats dosed orally for 4 months up to 50 mg salbutamol/kg BWt/day showed no histological 
changes and no evidence of toxicity was observed (Anon, 1971).  
In a 4-month dog study where oral doses of 0.02 to 25 mg salbutamol/kg BWt/day were 
administered and dose related tachycardia were observed with the most noted effect one hour 
after administration. At the higher doses, skin flushing was observed (Anon, 1971).  Similar 
results were observed with ractopamine at 0.002mg/kg BWt (EFSA, 2009), zilpaterol at 0.5 to 
1 mg/kg BWt (EFSA, 2016) and salmeterol at 0.15 to 2 mg/kg BWt (Owen, Beck, & Damment, 
2010).  It is however suggested that dogs are more sensitive to beta-adrenergic substances 
than other species i.e. monkeys and therefore the dog data is not considered when 
determining the NOAEL value for β-AA (EFSA, 2009).  
Cardiotoxicity was investigated in an oral study in rabbits at a dose of 150 mg salbutamol/kg 
BWt/day for 9 days.  No cardiac histological lesions or cardiac toxicity were detected (Poynter 
& Spurling, 1971). 
Yamada et al. (1977) investigated the effect of salbutamol in rats in a 1-month study at oral 
dosages of 17, 50 or 150 mg salbutamol/kg BWt/day. No changes were observed in 
electrocardiograms, blood biochemistry, urine analysis and haematology. Histological 
examination indicated a 13 - 27% increase in heart weight, muscle hypertrophy, interstitial 
oedema, congestion, focal myocardial necrosis and fibrosis as well as an increase in lung 
weight. These effects were however reversible after 1-month withdrawal of salbutamol and 
the findings where therefore not considered to be of toxicological significance but rather of 
pharmacological significance. 
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A range of subcutaneously administered β-AA cause myocardial necrosis due to the 
tachycardia which increases oxygen demand on the heart. The oxygen cannot be supplied to 
the heart as the coronary arteries are less perfuse during shortened diastole.  The severity of 
this effect varies depending on the number of beta-1 receptors stimulated (Stanton, Brenner, 
& Mayfield, 1969; Balazs, 1973). 
An unpublished study by Bhide (2010a) in Sprague-Dawley rats at daily oral dosages of 0, 6, 
12 and 24 mg R-salbutamol hydrochloride/kg BWt for 28 days led to reduced body weight in 
males in the 24 mg/kg BWt group. Increased relative weight of the adrenals were observed in 
the females from the 12 mg/kg BWt group. No related gross pathological or histological 
changes were seen, and the findings were not dose dependant and hence the findings were 
not considered to be of toxicological importance. No significant changes were observed in 
gross pathology or histopathology in the adrenals, aorta, brain, colon, duodenum, epididymis, 
eyes, hear, ileum, jejunum, kidneys, liver, lungs, lymph nodes, oesophagus, ovaries, skeletal 
muscle, skin, mammary gland, spleen stomach, testes, thymus, thyroid, urinary bladder and 
uterus. The NOAEL value for this study was therefore determined to be 12 mg R-
salbutamol/kg BWt. 
In a similar study by Bhide (2010b) in Swiss Albino mice at daily dosages of 0, 6, 12 and 24 
mg/kg BWt of R-salbutamol hydrochloride for 28 days, reduced body weights were observed 
in males in both the 24 mg/kg and 48mg/kg BWt groups. Also, an increased liver weight was 
observed in the 24 mg/kg BWt group and decreased kidney weights in the 24 and 48 mg/kg 
BWt groups. No significant changes were detected in gross pathology or histopathology in the 
adrenals, aorta, brain, colon, duodenum, epididymis, eyes, hear, ileum, jejunum, kidneys, 
liver, lungs, lymph nodes, oesophagus, ovaries, skeletal muscle, skin, mammary gland, spleen 
stomach, testes, thymus, thyroid, urinary bladder and uterus.  Similar to the previous study by 
Bhide (2010a), the NOAEL for R-salbutamol can be set at 12 mg/kg BWt. 
2.7.2 Carcinogenicity 
To assess the carcinogenic potential of an investigational veterinary drug, VICH Guideline 
GL28 (2005) recommends a 2-year rat study and an 18-month mouse study. 
Numerous studies with different β-AA have reported the formation of mesovarian leiomyomas 
in various rat strains and more specifically the Sprague-Dawley rat (Kelly, Marler, & Weikel, 
1993; Nelson & Kelly, 1971; Nelson, Kelly, & Weikel, 1972). Mesovarian leiomyomas were 
also found in long-term rat studies performed with salbutamol with dose related increases in 
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the incidence of leiomyomas of the mesovarian. These tumours were however found to be 
benign (Jack, Poynter, & Spurling, 1983; Poynter, Harris, & Jack, 1978; Tabachnick, 1981). 
Jack et al. (1983) indicated that the formation of the mesovarian leiomyomas were a function 
of the pharmacokinetic mode of action of salbutamol and terbutaline and not due to DNA-
reactivity. This was confirmed by the preventative action of concurrent administration of 
propranolol (a β-adrenergic blocker) in the development of the tumours. 
The use of long-term studies in rats has however been questioned as indicator of 
carcinogenicity effects of investigational drugs in humans (MacDonald, 2004). Rat ovary 
anatomy also differs from that of woman and the occurrence of mesovarian leiomyomas in 
woman is very rare and no increase in the incidence thereof has been observed over the last 
90 years with the use of beta-agonist as asthma treatment in humans (Poynter, Harris, & Jack, 
1978). 
Also, no similar development of mesovarian leiomyomas were seen in any long-term studies 
in mice, dogs, non-human primates or hamsters (Poynter, Harris, & Jack, 1978; Tabachnick, 
1981).  In an 18-month study with CD-1 mice, no evidence of tumour development was 
observed at oral doses up to 500 mg salbutamol/kg BWt and in a 22-month study in Golden 
Hamsters dosed up to 50 mg salbutamol/kg BWt, no tumour development was observed 
(Brambilla, Mattioli, Robbiano, & Martelli, 2013). 
Rat carcinogenicity study data can therefore be excluded as a carcinogenicity indicator for 
humans (Jack, Poynter, & Spurling, 1983). Salbutamol is therefore not carcinogenic in 
humans. This is similar to the findings of the EFSA in their safety evaluation of both 
Ractopamine (EFSA, 2009) and Zilpaterol (EFSA, 2016). 
2.7.3 Genotoxicity 
Genotoxicity studies are performed to investigate any damage that a veterinary drug might 
have with respect to DNA and its fixation. 
As outlined in VICH guideline GL23 (2014) the studies generally required to assess the 
genotoxic potential of an investigational new veterinary drug are as follows: 
1. A test for gene mutation in bacteria
2. In vitro test for chromosomal effects in mammalian cells
3. In vivo test for chromosomal effects using rodent hematopoietic cells
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Brambilla et al. (2013) reported that no genotoxicity was observed in any of the genotoxicity 
assays for racemic salbutamol as summarised in Table 2.2. 
Table 2.2: Genotoxic effect of salbutamol 
Test System 
Results Dose 
LED or HID Without e.m.s. With e.m.s. 
S. typhimurium TA98, TA1537, 
TA1538, reverse mutation 
- - NR 
E. coli WP2, WP2 uvrA, WP67, 
reverse mutation 
- - NR 
Saccharomyces cerevisiae, 
forward mutation 
- - NR 
Saccharomyces cerevisiae, 
mitotic gene conversion 
- - NR 
Chromosomal aberrations, human 
lymphocytes in vitro 
- - NR 
LED, lowest effective dose; HID, highest ineffective dose; NR, not reported; without e.m.s., without exogenous 
metabolic system; with e.m.s., with exogenous metabolic system. 
The genotoxicity of salbutamol has been evaluated as part of the New Drug Application (NDA 
20-837) with the U.S. Food and Drug Administration (FDA) by Sepracor and evaluated in both 
the bacterial test for gene mutation, and the in vitro test for chromosomal effects in mammalian 
cells (Whitehurst, 1999). 
The bacterial gene mutation test was conducted for NDA 20-837 and evaluated the ability of 
salbutamol, in the presence and absence of rat microsomal enzyme (S9), to induce reverse 
mutation at specific histidine loci in 5 Salmonella typhimurium test strains (TA1535, TA1537, 
TA98, TA100 and TA102) and at the tryptophan locus in Escherichia coli test strain WP2uvrA. 
A non-reproducible increase in reversion frequency was observed with strain TA100 and 
TA1537 (both with S9 only) and was not statistically significant nor dose dependent at 
concentrations ranging between 5000-10,000 µg/plate (Whitehurst, 1999). 
An in vitro test for chromosomal effects was carried out in the Chinese hamster ovary (CHO)/ 
HPRT mammalian cell forward gene mutation assay. The CHO cells were incubated in the 
presence and absence of S9 at 10 concentrations ranging from 0.167 - 5000 µg/ml. While R-
salbutamol was shown to be cytotoxic at 5000 µg/ml, all average mutant frequencies were 
within negative control ranges (Sepracor Inc., 1999). 
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Libretto (1993) and Xopenex FDA Approved Extended Label (Sepracor Inc., 1999) note that 
salbutamol was not mutagenic in vitro against four bacterial strains with or without metabolic 
activations (liver microsomes) and at concentrations of up to 1 million times its effective 
concentration. No mutagenic activity was detected in Kada's reversion and recombination test 
or Zimmerman's' reversion and mitotic gene conversion test. 
These original results point towards a favourable outcome in the battery of genotoxicity testing. 
A chemical's genotoxicity test results are recognized as an indicator of its carcinogenic 
potential since many carcinogens have a genotoxic mode of action (VICH GL28 I CVM 141). 
Hence a negative test battery supports the request that carcinogenicity tests may not be 
required. The CVM Guideline 141 further states that "because it is generally believed that non-
genotoxic compounds exhibit a threshold dose for carcinogenicity and human exposure to 
residues of veterinary drugs is low, non-genotoxic compounds should not be routinely tested 
for carcinogenicity." In addition to the studies summarized above, results from non-radio-
labelled tissue residue studies with R-salbutamol and its racemate demonstrate that the 
residue levels associated with chronic administration to livestock will be in orders of magnitude 
below the corresponding therapeutic dose in humans (Malucelli, Ellendorff, & Meyer, 1994). 
Furthermore, stereo-selective pharmacokinetic studies have demonstrated that in humans, 
the systemic availability of orally administered R-Salbutamol is very low due to extensive pre-
systemic metabolism (Boulton & Fawcett, 1996b). 
Lack of genotoxicity is often a good indication that carcinogenicity is unlikely. Coupled with a 
long history of use in humans for the control of asthma with no evidence of a carcinogenic link, 
there appears substantiated scientific evidence to suggest that R-salbutamol is not 
carcinogenic and to argue against the need for R-salbutamol specific carcinogenicity studies. 
2.7.4 Reproductive and Foetal Toxicity (teratogenic effect) 
No impairment of fertility was observed in a reproductive rat study at oral doses of up to 50 
mg salbutamol/kg BWt/day (Sepracor Inc., 1999; Health Products Regulatory Authority, 1983). 
However, studies using radio labelled racemic salbutamol administered either intraperitoneally 
or intravenously in pregnant rats have shown some transfer of radio labelled material to the 
foetus equal to 10% of the maternal plasma radioactivity (Gardey-Levassort, Richard, 
Hauguel, Thiroux, & Olive, 1982). According to Hauguel et al. (1982), an increase in foetal 
plasma insulin levels were observed prior to an increase in blood glucose concentration after 
a single salbutamol injection of 600 µg/kg BWt at 21 days of gestation. A chronic daily infusion 
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of 600 µg/kg BWt from day 6 to 20 of gestation led to a decrease in the insulin-secreting ability 
of the foetus following a glucose injection to the pregnant mother. This however did not have 
any effect on the glycogen content of the placenta or foetal liver nor on birth weight.  
Salbutamol may also delay preterm labour as it interferes with uterine contractility. Salbutamol 
is classified as Pregnancy Category C (risk cannot be ruled out). Salbutamol is used 
therapeutically in humans to delay onset of birth by reducing uterine contractions specially to 
prevent premature labour (Gummerus, 1981). 
A single-generation embryo-foetal study was performed in New Zealand White Rabbits and 
no embryo or foetal toxicity was observed after R-salbutamol was administered orally at doses 
up to 25 mg/kg BWt/day during days 6 - 20 of pregnancy (Sepracor Inc., 1999; Whitehurst, 
1999). 
Results in studies performed on pregnant mice showed cleft palate malformations in 9.3 % of 
foetuses of females dosed subcutaneously at a dosage of 25 mg salbutamol/kg BWt/day and 
in 4.5% of foetuses from pregnant females dosed subcutaneously at 0.25 mg salbutamol/kg 
BWt/day. No cleft palate formation was observed when salbutamol was administered 
subcutaneously at 0.025 mg/kg BWt/day. However, 30.5% of foetuses from the positive control 
group (2.5 mg isoproterenol/kg BWt/day) presented with cleft palate.  No statistical differences 
were noted between the incidence of cleft palate between the treatment and control groups. 
In identical trials where salbutamol was administered subcutaneously in pregnant rabbits and 
rats, no cleft palate was observed in foetuses (Sepracor Inc., 1999; Szabo, Difebbo, & Kang, 
1975; Whitehurst, 1999).  
It is important to note that the subcutaneous dosing in pregnant animals can lead to an 
increase in the output of endogenous steroids due to stress, which can lead to the increased 
incidence of cleft palate (Barlow, Morrison, & Sullivan, 1975). Cortisone, the endogenous 
steroid hormone secreted during stress, delays the rate at which the palate shelf moves during 
embryonic development and in doing so prevents the fusion of the shelves, leading to cleft 
palate (Walker & Fraser, 1957). 
In pregnant rats dosed orally at dosages of 0.5, 2.32, 10.75 and 50 mg salbutamol/kg BWt/day 
no foetal abnormalities were observed. Neonatal mortalities were observed at the highest 
dosage level of 50 mg/kg BWt/day which was attributed to a lack of maternal care and not due 
to any direct effect of salbutamol (Health Products Regulatory Authority, 1983). 
Cranioschisis were observed in 37% of foetuses from Stride Dutch Rabbits treated orally with 
50 mg salbutamol/kg BWt/day (Sepracor Inc., 1999; Whitehurst, 1999) 
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Congenital abnormalities, such as cleft palate or limb deformation, have rarely been reported 
in the offspring of human patients being treated with salbutamol (Sepracor Inc., 1999; 
Whitehurst, 1999).  
As the preferred species for toxicological evaluation is the rat in this instance and the route of 
exposure is oral, the NOAEL can be set at 10.75 mg/kg BWt/day from the study in pregnant 
rats for the teratological effect (Health Products Regulatory Authority, 1983). 
2.7.5 Acute oral toxicity – single dose studies 
Acute oral toxicity of racemic Salbutamol (R+S-salbutamol) results depend on whether the 
animal has been fed or fasted. Fed rats tolerate salbutamol and other β-AA better than when 
fasted. This can be attributed to the higher Cmax (the maximum plasma concentration achieved 
following oral dosage of the drug investigated) and shorter Tmax (the time to reach Cmax) as a 
result of accelerated gastric emptying in fasted animals (the β-AA is absorbed more rapidly). 
The higher Cmax will ultimately result in more pronounced acute effects (Kast & Nishikawa, 
1983).  For the purpose of determining the ADI for possible residues consumed by humans, 
only oral studies in fed animals will be considered as the residues in animal tissue consumed 
by humans will naturally always be part of a meal. 
LD50 is usually determined in acute toxicity studies.  The LD50 is defined as the level of drug or 
substance given to test subjects that is enough to kill 50% of the test population (Duffus, 2006). 
A LD50 of 8600 mg salbutamol/kg BWt was reported by Kast and Nishikawa (1983) in orally 
dosed male Sprague-Dawley rats (8-week old) and 7600 mg salbutamol/kg BWt in females 
fed rats. A LD50 in excess of 2000 mg salbutamol /kg BWt was also reported in a trial with rats 
and mice (Anon, 1971). 
According to the Globally Harmonized System of Classification and Labelling of Chemicals 
(GHS) a chemical with a LD50 between 2000 mg/kg BWt and 5000 mg/kg BWt is classified as 
Category 5 acute toxicity, with Category 1 representing the most hazardous and Category 5 
the least hazardous with regards to acute toxicity.  The LD50 of salbutamol indicates a  category 
5 classification for salbutamol. 
It is important to note that the metabolism of salbutamol in animals differ to that in humans. 
Sulphate conjugation is the main route of metabolism of salbutamol in humans with the 
sulphate conjugate being metabolically inactive. The sulphate conjugation in humans takes 
place in the intestines (presystemic) and in the liver (first-pass). Of the ingested dose 48.4% 
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were excreted as the sulphate conjugate in humans whilst the bioavailability was found to be 
50% of the oral dose (Morgan, Paull, Richmond, Wilson-Evered, & Ziccone, 1986). Metabolism 
of salbutamol is also different between animal species with major differences also being noted 
between animals. Salbutamol is metabolised by glucuronic acid conjugation (Martin, Hobson, 
Page, & Harris, 1971) in animals compared to sulphate conjugation in humans.  Martin et al. 
(1971) investigated the difference in metabolism of salbutamol between species.  In rats, 90% 
of the excreted salbutamol in urine was as the metabolite.  In dog studies, between 0% and 
30% of excreted salbutamol in urine was in the form of the metabolite. Therefore, using animal 
acute data for determination of human safety has little scientific merit. With the number of 
human studies performed with salbutamol it is therefore more pertinent to determine human 
safety based on the available human study data.  
The other important aspect to note is the difference in enantio-selectivity of salbutamol (R- or 
S-).  Most studies were performed using the racemic formulation.  It is however clear that there 
are major differences in the metabolism as well as the effects of the enantiomers of salbutamol 
as discussed in section 2.4.3.  
Evaluating the data on the enantiomers of salbutamol, it has been shown that the R-isomer is 
biologically active at the receptor site whereas the S-isomer is viewed as being inactive 
(Boulton & Fawcett, 1997). 
In human trials, the plasma levels of R-salbutamol are much lower than that for S-salbutamol 
or the racemate dosed individually.  However, the effect on heart rate after oral dosage of R-
salbutamol is similar to that of the racemate when the racemate is dosed at double the level 
of R-salbutamol.  A dose of 5 mg R-salbutamol results in a plasma Cmax of ~2.5 ng/ml whereas 
10 mg of the racemate translates into a plasma Cmax of ~3.5 ng/ml R-salbutamol (Boulton & 
Fawcett, 1997).   
It is therefore safe to assume that the possible adverse effects of R-salbutamol can be 
compared to that of the racemate in humans when investigating the safe intake levels for 
humans at equipotent dosages.    
Boulton and Fawcett (1996b), gave seven healthy volunteers a single dose of 1.6 mg racemic 
salbutamol intravenously per person and 4 mg racemic salbutamol per person orally.  Loading 
doses were given to the participants the day before the start of the oral phase of the study. 
Three 4 mg racemic salbutamol sulphate oral doses were ingested every 8 hours.  At the start 
of the oral study, a fourth 4 mg oral dose were administered 8 hours following the last oral 
dose.  The R- and S-salbutamol levels were determined in plasma and urine was collected at 
Stellenbosch University  https://scholar.sun.ac.za
33 
specified time-points. At the same time-points, the heart rates were monitored. Figure 2.7 
below summarises the data findings in the trial for heart rate and plasma levels for both 
intravenous and oral doses. 
The Cmax value for R-salbutamol when dosing the racemate at 4 mg per person was ~3.5 ng/ml 
plasma. The oral dose of racemic salbutamol caused a slight increase in heart rate of 10 ± 4 
beats per minute which as expected, gradually decreased back to normal as the plasma level 
of salbutamol decreased.  At a plasma level of ~1 ng/ml R-salbutamol there was zero effect 
on the heart rates in the volunteers.  These results are similar to the findings of Morgan et al. 
(1986) where a 4 mg oral intake of racemic salbutamol increased heart rate by 10 beats per 
minute. 
Figure 2.7: Mean (± s.e. mean) hourly heart rates (beats/min) () and plasma concentrations (ng/ml) 
for S- (), and R- () salbutamol following (a) intravenous administration (1.6 mg) and (b) the fourth 
hourly oral dose (4.0 mg) of racemic salbutamol sulphate (Boulton & Fawcett, 1996b). 
In a similar trial by Boulton and Fawcett (1997) comparing the pharmacokinetics of racemic 
salbutamol with that of R-salbutamol and S-salbutamol, lower plasma peak levels were 
observed for R-salbutamol, confirming the lower systemic bio-availability and shorter half-life 
of R-salbutamol as seen in Figure 2.8. 
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Figure 2.8: Plasma concentration-time profiles for R-salbutamol () and S-salbutamol () after oral 
administration of 5 mg R-salbutamol (A), 5 mg S-salbutamol and 10 mg racemic salbutamol (mean ± 
SEM) (Boulton & Fawcett, 1997) 
Due to the much higher dose of R-salbutamol in this study of 5 mg R-salbutamol and 10 mg 
racemic salbutamol per person compared to 4 mg racemic salbutamol per person in the 
previous study by Boulton and Fawcett (1971), the increase in heart rate was slightly more 
pronounced (Figure 2.9), but there were no significant differences between the R-salbutamol 
and racemic salbutamol treatments at most time points. Heart rate was back to normal at 
plasma levels of ~1 ng/ml, confirming the results from the previous study by Boulton and 
Fawcett (1971). 
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Figure 2.9: Pharmacodynamic response-time profile for heart rate after oral administration of 5 mg R-
salbutamol (), 5 mg S-salbutamol () and 10 mg racemic salbutamol () (mean ± SEM) (Boulton & 
Fawcett, Pharmacokinetics and pharmacodynamics of single oral dose of Albuterol and its enantiomers 
in humans, 1997) 
From the observations of Boulton and Fawcett (1996b), accepting a linear response between 
dose and plasma level, it can be calculated that an oral dose of  ̴1.6 mg racemic salbutamol 
will result in a maximum S-salbutamol plasma level of 4 ng/ml and R-salbutamol concentration 
of 1 ng/ml.  At these levels, no clinical measurable heart rate effects were present. It should 
be noted that the racemate results in competition for elimination of R-salbutamol which is not 
the case when the pure R enantiomer is administered (Boulton & Fawcett, 1996b). 
In the study by Boulton and Fawcett (1997), a 5 mg dose of R-salbutamol per person led to a 
Cmax of   ̴ 2.5 ng/ml in plasma.  Heart rate were back to normal at a plasma concentration 
of  ̴1ng/ml R-salbutamol.  Applying the same calculation as above, this gives a value of 2 mg 
oral R-salbutamol as the safe dose for R-salbutamol in humans where no acute adverse 
effects will be noticeable. At these levels, no clinical measurable effects were present (i.e. 
heart rate, plasma glucose, and potassium and / or ECG changes).  This equates to a NOAEL 
value for R-salbutamol of 33.33 µg/kg BWt. Alternatively, a LOAEL (lowest adverse effect 
level) value of 66.66 µg/kg BWt can be set from the above study with R-salbutamol at a single 
dose of 4 mg per person (average volunteer body weight = 75 kg in the Boulton and Fawcett 
study (1996b)). 
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2.7.6 Toxicological Conclusion 
No genotoxicity or carcinogenesis were noted in the reported data above. This agrees with 
the conclusion of the FEEDAP panel that reviewed the safety of ractopamine.  The FEEDAP 
panel did not consider ractopamine to be carcinogenic or genotoxic (EFSA, 2009).  Similarly, 
EFSA in their evaluation of the JECFA report concluded that zilpaterol is also unlikely to be 
carcinogenic or genotoxic (EFSA, 2016). 
No reproductive toxicity was noted for salbutamol and is in line with similar findings for 
zilpaterol (EFSA, 2016) and ractopamine (EFSA, 2009). 
Congenital abnormalities were noted for salbutamol and a NOAEL for teratology can be set at 
10.75 mg/kg BWt/day based on the oral dose study in pregnant rats (Health Products 
Regulatory Authority, 1983). This is similar to the NOAEL values for ractopamine of 15 mg/kg 
BWt set for teratological effects in pregnant rats (EFSA, 2009) and 0.2 mg/kg BWt for zilpaterol 
due to teratological effects in pregnant rats and rabbits (EFSA, 2016). 
Repeat dose toxicity studies indicated a NOAEL of 12 mg salbutamol/kg BWt/day for R-
salbutamol in Swiss Albino mice (Bhide, 2010b).   
A NOAEL of 10.75 mg /kg BWt/day was determined from the teratological effects in foetuses 
from pregnant rats (Health Products Regulatory Authority, 1983).   
2.8 Acceptable Daily Intake (ADI) Calculations 
2.8.1 Standard Method of Calculation 
The standard accepted method as drafted by the Committee for Veterinary Medicinal Products 
(CVMP), which forms part of The European Agency of the evaluation of Medicinal Products 
(EMEA) (CVMP EMEA, 2001), for the determination of an ADI is to first establish a NOAEL 
and thereafter determine a satisfactory uncertainty factor (UF). Uncertainty factors are applied 
when extrapolating data from the toxicity observed in laboratory animals to health risks in 
humans, this usually being a factor of 10 for interspecies difference and a factor of up to 10 
for human variability (depending on the extent and quality of available human data) (Lozano 
& Trujillo, 2012).  Additional uncertainty factors can be applied depending on the nature of the 
toxic effect.  Toxic end points which has been given additional factors include, carcinogenicity, 
teratogenicity and where steep dose responses are seen above the NOAEL (Renwick, 1995). 
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Calculation of the ADI for R-salbutamol can therefore be as calculated from the NAOEL value 
of 10.75 mg/kg BWt/day as described in the rat maternal and foetal toxicity study (section 
2.7.6).  The only effect observed in this study (Health Products Regulatory Authority, 1983) 
was neonatal mortalities, at 50 mg/kg BWt/day, which was attributed to a lack of maternal care 
and not due to any direct effect of salbutamol.  According to Renwick (1995) an additional 
uncertainty factor cannot be applied to one study due to an observed effect through a different 
route of administration (oral vs. subcutaneous) or between studies in different species (i.e. 
rabbits vs. rats). The importance of possible teratological effects can however not be ignored 
and an additional safety factor of 10 is suggested to be applied in this instance as pregnant 
mothers can potentially ingest residues of salbutamol in tissue from animals treated with R-
salbutamol. 
The formula used to calculate the ADI (expressed as mg/kg BWt/day) is as follows (CVMP 
EMEA, 2001):   
𝐴𝐷𝐼 =  
𝑁𝑂𝐴𝐸𝐿
𝑈𝐹
𝐴𝐷𝐼 =  
10.75 mg/kg/𝑑𝑎𝑦
(10 × 10 × 10) 
= 0,011 𝑚g/kg BWt/day 
The total ADI expressed on a body weight basis using 60 kg BWt as the standard adult human 
weight. The total ADI would therefore be 0.66 mg/day. 
2.8.2 Alternative published ADI Calculation 
In a report compiled by the Institute of Environment and Health (Holmes, et al., 2007) for the 
Department for Environment Food and Rural Affairs, UK Government, a NOAEL of 17 mg/kg 
BWt/day for cardiotoxicity from a one-month oral study in rats was used. To allow an 
assessment of the calculated racemic salbutamol intakes, a project-specific ADI of 0.017 
mg/kg BWt/day was derived by dividing the NOAEL by a total uncertainty factor of 1000 to 
allow for intra- and inter-species variation with an additional factor of 10 due to the limited 
amount of data available in the review by Holmes et al. (2007).  
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2.8.3 FDA Adopted Alternative Method for ADI Calculation 
The FDA has adopted a new method for calculating ADI for MRL determination based on 
actual human data. This method is based on the research of Matthews et al. (2004) who 
investigated the use of human data derived from pharmaceutical clinical trials to estimate the 
NOEL value of a molecule rather than relying on laboratory animal models.  They believe that 
this data provides a more specific estimate of the toxic effects of molecules in humans than 
the historically used values extrapolated from animals with assumed safety factors applied. 
This investigated value is referred to as the Maximum Recommended Therapeutic Dose 
(MRTD). The values for the investigated molecules can be found in the FDA Maximum 
(Recommended) Daily Dose Database (Benz, 2013). 
According to Matthews et al. (2004) the NOAEL is defined as MRTD/10. The MRTD for 
salbutamol was set at 0.533 mg/kg BWt/day. 
Therefore: 
𝑁𝑂𝐴𝐸𝐿 =  
MRDT
10
=
0.533 𝑚𝑔/𝑘𝑔
10
= 0.053 𝑚g/kg BWt/day 
The uncertainty factor of species difference will not apply in this calculation as the NOAEL is 
derived from human data.  A 10 times uncertainty factor should however be applied to account 
for individual differences.   
𝐴𝐷𝐼 =  
NOAEL
10
=  
0.0533 𝑚𝑔/𝑘𝑔
10
= 0.0053 𝑚g/kg BWt/day 
The ADI for a 60kg adult human would therefore be 0.032 mg/day. 
2.9 Acute Reference Dose Calculation 
Since R-salbutamol would most probably have a greater acute than chronic effect. (Boulton & 
Fawcett, 1996b), it is important to calculate the Acute Reference Dose (ARfD) for R-
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salbutamol. These acute effects are dose dependant and include tremors, tachycardia, heart 
palpitations and muscle cramps (Health Products Regulatory Authority, 1983). 
The basic approach for the derivation of an ARfD is based on the identification of an 
appropriate point of departure (POD), or threshold, for the pharmacological or toxicological 
endpoint of concern. This is typically identified as a NOAEL or bench mark dose lower 
confidence limit (BMDL). The ARfD is determined by dividing this POD (or NOAEL) by an 
appropriate Uncertainty Factor (UF) (JECFA, 2016).  
The ARfD can be reported as an amount of the substance expressed on a per person or body 
weight basis (e.g. mg/person or mg/kg body weight)  
The formula for calculation of the ARfD is (JECFA, 2016): 
𝐴𝑅𝑓𝐷 =  
𝑃𝑂𝐷
𝑈𝐹
Where: 
 POD is the point of departure or threshold for pharmacological or toxicological effects
of concern (alternatively referred to as the NOAEL)
 UF is an uncertainty or safety factor, or series of factors that typically account for
considerations such as animal to animal variability, interspecies extrapolation, quality
of data, severity of response, etc.
In the EFSA (2016) evaluation of Zilpaterol, the ARfD was also chosen to be the most accurate 
indicator of human safety rather than the ADI calculated from chronic studies.  The available 
data used were from a LOAEL set at 0.00076 mg/kg BWt derived from a study in asthmatic 
patients. The uncertainty factor applied was 10 for individual variability and a factor of 2 due 
to the use of a LOAEL value instead of a NOAEL value. The ARFD for zilpaterol were 
subsequently set at 0.00004 mg zilpaterol/kg BWt per day. 
Similarly, the EFSA evaluation (2009) for ractopamine used a NOAEL value of 0.067 mg/kg 
BWt but due to the experimental weaknesses in the human trial assessed, an uncertainty 
factor of 50 (10 for individual variability and 5 for uncertainty of the data from the human trial) 
was applied. The ARfD for ractopamine were set at 0.001 mg ractopamine/kg BWt per day.   
If the LOAEL value of 0.067 mg R-salbutamol/kg BWt as calculated in section 2.7.5 and the 
formula as used in the zilpaterol EFSA evaluation (2016) is applied the ARfD for R-salbutamol 
will be as follows: 
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𝐴𝑅𝑓𝐷 =  
𝑃𝑂𝐷
𝑈𝐹
𝐴𝑅𝑓𝐷 =  
 0.067 mg/kg BWt
20
𝐴𝑅𝑓𝐷 =   0.003 mg/kg BWt 
Should we use the derived NOAEL as calculated in section 2.7.5 the factor of 2 for correction 
of data derived from a NOAEL value instead of a LOAEL can be excluded and only a factor of 
10 need to be applied. The POD of R-salbutamol for the calculation of the ARfD is therefore 
0.033 mg/kg BWt. The calculation is thus as follows: 
𝐴𝑅𝑓𝐷 =  
𝑃𝑂𝐷
𝑈𝐹
𝐴𝑅𝑓𝐷 =  
 0.033 mg/kg BWt
10
𝐴𝑅𝑓𝐷 =   0.003 mg/kg BWt 
The two methods of calculations calculated to the same value and therefore would indicate 
that the calculation of the NOAEL value from the Boulton and Fawcett (1997) trial is accurate. 
2.10 ADI or ARfD? 
The ADI’s calculated from the long-term toxicity studies as well as the three additional 
published methods (CVMP EMEA, 2001; Holmes, et al., 2007; Matthews, Kruhlak, Benz, & 
Contrera, 2004) range from 0.011 – 0.53 mg/kg BWt.   
As stated in section 2.6, the ARfD would be considered if it is lower than the ADI and below 
1mg/kg BWt.   
All the required criteria have been met as discussed above and as both the safe intake level 
for zilpaterol (EFSA, 2016) and ractopamine (EFSA, 2009) are also based on the ARfD, the 
ARfD of 0.003 mg/kg BWt (rounded as per JECFA standard procedure) will be used as the 
safe maximum intake for R-salbutamol.  The ADI in humans for R-salbutamol can therefore 
be set at 0 - 3 µg/kg BWt using the ARfD as the upper limit of the ADI (JECFA expresses ADI 
as µg/kg BWt). 
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2.10.1 Human safety conclusion 
Comparing the calculated ADI (derived from the ARfD) of that R-Salbutamol (<3 µg/kg BWt) 
with that of Zilpaterol (0 - 0.04 µg/kg BWt) (EFSA, 2016) and Ractopamine (0 - 1 µg/kg BWt) 
(EFSA, 2009) it is apparent that R-Salbutamol has a higher safety margin in humans than 
either Zilpaterol or Ractopamine. 
2.11 Conclusion 
The improved safety profile of R-salbutamol in comparison to currently available β-AA for use 
in food producing animals warrants further investigation into the residue levels of R-salbutamol 
in cattle and sheep to determine the MRL as well as determine a safe withdrawal period of R-
salbutamol for use in cattle and sheep feedlot production. 
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CHAPTER 3 
R-SALBUTAMOL RESIDUE DEPLETION STUDY IN FEEDLOT LAMBS 
ABSTRACT 
This study investigated the residue kinetics and target animal tolerance of R-salbutamol in 
feedlot lambs. Group A consisted of one randomly selected lamb slaughtered as the 
negative control to indicate that there were no residues occurring naturally within the test 
flock.  Group B and C (6 lambs each) were fed 21 mg R-salbutamol per day (0.5 mg/kg BWt) 
in feed for 28 days.  Heart rate, respiratory rate and rectal temperature were recorded at day 
-1 and 28.  R-salbutamol was withdrawn from the feed for 7 hours prior to slaughter (group 
B) and 24 hours prior to slaughter (group C).  Liver, kidney, muscle and fat samples were
collected and analysed for salbutamol residues (LC-MS/MS). No significant differences were 
observed in heart rate in the non-medicated and medicated period. Significant differences 
were observed for rectal temperature and respiratory rate between day -1 and 28. Rectal 
temperature differences were of no clinical significance and within the normal range.  The 
difference in respiration rate were attributed to lower respiratory infection. No visual adverse 
events were observed in the study lambs.  Salbutamol residues were highest in the liver, 
followed by kidney, muscle and fat at both withdrawal times. Almost ninety percent of all 
parent salbutamol residues were present in the liver.  At 24 hours the average muscle 
residue was below the limit of quantification. Residue levels were more than 50% lower at 
24 hours withdrawal compared to the levels at 7 hours. The theoretical maximum daily intake 
of salbutamol for humans is less than 10% of the acceptable daily intake. Therefore, in 
conclusion, the animal tissue from feedlot lambs fed R-salbutamol according to the 
prescribed dosage in feed, will provide adequate consumer protection at zero-day 
withdrawal. 
3.1 Introduction 
Beta-adrenergic agonists (β-AA) have been researched and used in the feedlot industry for 
more than 30 years (Merck Animal Health, 2017). Zilpaterol was the first beta-agonist to be 
investigated and registered for use as a growth enhancer in feedlot cattle. Today, Zilpaterol is 
widely used in sheep feedlots in South Africa under veterinary prescription, as no commercial 
zilpaterol product has been registered with the Fertilizer, Farm Feeds, Agricultural Remedies 
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and Stock Remedies Act of 1947 (Act 36 of 1947) as a stock remedy for use in feedlot lambs 
(Allen, 2015). In fact, as far as could be ascertained, no zilpaterol product is registered for use 
in feedlot lambs anywhere in the world. Zilpaterol has however been tested extensively in 
feedlot lambs and the efficacy as a growth enhancing technology has been confirmed 
(Estrada-Angulo, et al., 2008; López-Carlos, et al., 2010; López-Carlos, et al., 2011; Pringle, 
Calkins, Koohmaraie, & Jones, 1993; Vahedi, et al., 2014; Webb, Allen, & Morris, 2018).  An 
official safety evaluation by the European Food Safety Authority (EFSA) has not been done 
on the residue kinetics of zilpaterol in lambs and no official withdrawal period has been 
determined in feedlot lambs.  No published data on residue kinetics of Zilpaterol in sheep 
could be found. 
A new selective β2-AA, Salbutamate 10% (R-salbutamol sulphate – 100 g/kg) has been 
registered in South Africa (Reg. No. G4084 (Act 36 of 1947)) for feedlot cattle and lambs 
(Animate Animal Health, 2017). The need for a registered, safe β-AA growth enhancer for 
feedlot lambs was identified and subsequent production research has been done on the 
possibility for use in feedlot lambs (De Klerk, 2016; Du Toit, 2017).  As part of the registration 
intent, research had to be completed with regards to the metabolism and residue kinetics of 
R-salbutamol in feedlot lambs. 
Due to the varying half-life, metabolism and excretion between species and between 
molecules within the β-AA class, species specific research with regards to the metabolism and 
residue depletion is of utmost importance.  According to the VICH Guidelines (VICH Steering 
Committee, 2015) the purpose of such trials is to demonstrate the depletion of the marker 
residue once the drug is withdrawn from treatment and to determine how long after withdrawal 
a regulatory safe residue level is reached. In the case of R-salbutamol, an international 
Maximum Residue Limit (MRL) has not been set and as part of this study the suggested MRL 
will be calculated to assist in determining the safe level in tissue for human consumption and 
subsequent safe withdrawal period.  
3.2 Materials and Methods 
The research project was approved by Animal Ethics – ARC: Animal Production Institute 
(Irene) (APEIC15/06) and handling and housing of all animals were conducted according to 
the South African National Standards 10386: 2008. 
The trial was conducted at the Agricultural Research Council: Animal Production Institute 
facility (Irene, Gauteng, South Africa). 
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3.2.1 Animals 
The animals used in this study were male, Dorper type lambs (4-5 months of age) with and 
average weight of 42.53 ± 1.14 kg at arrival. Animals were purchased from Cavalier Feedlot, 
Kameeldrift, Pretoria. Thirteen lambs were randomly allocated to one of three groups 
according to a randomised, parallel group design.  The individual ovine were the experimental 
unit in this study. 
3.2.2 Housing 
Indoor stable units with individual metabolic stanchions were used during the trial.  Stables 
were not environmentally controlled and environmental conditions fluctuated with ambient 
conditions. The lambs were able to socialise through visual interaction as the stanchions were 
next to each other and divided by metal bars. Physical interaction was however restricted. 
The identification number of the lamb housed inside a stanchion, the study number, brand of 
feed and feed quantity were indicated on the outside of each stanchion. The size of each 
indoor stanchion was 1.5 m2. 
Routine practices were standardised across all animals. All lambs were at the study facility for 
7 days prior to the start of the R-salbutamol administration. 
Prior to the start of the trial the facility was washed and cleaned, and stanchions and the floor 
of the house were washed at the end of each day to ensure health and hygiene of the animals. 
3.2.3 Feed and water 
The rams purchased was already processed and fed a grower ration at the feedlot.  Therefore, 
feed acclimatisation was not required once they arrived at the trial facility. A balanced, 
commercial sheep feedlot finisher ration, sourced from Cavalier Feedlot, Kameeldrift, Pretoria 
was fed (Table 3.1).  Feed requirement adjustments were made daily by observing animal 
behaviour associated with feeding.   
Feed and potable water were supplied in containers at the front of the stanchion. 
A 250 g specimen of each batch of feed was collected and analysed to confirm that no levels 
of R-salbutamol were present in the feed received from Cavalier Feedlot. 
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Table 3.1: Nutrient composition of sheep feedlot finisher ration 
Nutrient Quantity (g/kg) 
Crude Protein 160 
Fat 50 
Fibre 170 
Moisture 120 
Calcium 10 
Phosphorus 2 
3.2.4 Experimental Procedure 
Two groups of six animals each received R-salbutamol orally in feed twice daily for 28 days. 
Feeding of animals were according to Standard Operating Procedures: SR006 – Small 
Ruminants – Dispensing feed to animals in metabolic crates (Agricultural Research Centre, 
Irene).  Lambs was fed twice daily at 8am and 4pm.  During the acclimation phase the intake 
of each individual lamb was determined to ensure that each lamb consumed 100% of its daily 
feed.  Leftover feed was weighed each afternoon and the next day’s feed allocation was 
adjusted accordingly.  Each animal received 21 mg R-salbutamol per animal per day (± 0.5 
mg/kg body weight (BWt) at start weight).  The daily dosage of R-salbutamol was divided in 2 
equal doses and administered as a top-dressing to the feed for a period of 28 days. R-
salbutamol was administered as a feed additive, as it will be marketed and sold as a feed 
additive for feedlot lambs. R-salbutamol was used at the intended dose, dosage frequency 
and duration required to imitate the sheep feedlot situation. 
Personnel wore overcoats, impervious gloves and a dust mask during administration and 
handling of R-salbutamol and the medicated feed. 
3.2.5 Animal handling 
The lambs were handled by personnel in the stanchion during clinical examination. Animals 
were loaded on to a vehicle for transport to the on-site abattoir at the end of the study. The 
abattoir is situated on site at the ARC-API Irene. No other methods of restraint were applied.  
3.2.6 Animal Observations 
General health observations were performed daily throughout the the study.  The aim of the 
general heath observation was to detect any health issues that may warrant veterinary care 
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or constitute withdrawal of animals from the study. These observations included, but were not 
limited to, habitus, appetite, colour of urine, colour and consistency of faeces, salivation, 
vomiting, skin lesions and an obvious change in general health condition. 
Clinical examinations were performed once during the acclimatisation period 2 days prior to 
the start of the medication period (at 10:00 in the morning) and again on the last day of the 
medication period (at 8:45 in the morning). These examinations included heart rate, respiratory 
rate and rectal temperature. Clinical observations were performed in the station following a 
period with the animal to allow them to get used to the handler. Heart rate was determined by 
means of a stethoscope held on the left side of the thorax (low third intercostal space).  Beats 
per minute were counted for 15 seconds, multiplied by 4 and recorded. Respiratory rate was 
determined by counting chest movement for a 15 second period and multiplying it by 4.  Rectal 
temperature was measured with a digital thermometer placed in the rectum of the sheep 
following heart rate and respiratory rate monitoring.  
The first observation was to determine the clinical parameters prior to the start of the R-
salbutamol treatment and the observations at the end of the study, prior to withdrawal of R-
salbutamol, were to determine if R-salbutamol had any effect on heart rate, respiratory rate 
and rectal temperature. 
3.2.7 Feed withdrawal and slaughter schedule 
The trial design is based on the VICH guideline GL48 (Studies to evaluate the metabolism and 
residue kinetics of veterinary drugs in food-producing animals: Marker residue depletion 
studies to establish product withdrawal periods) (VICH, 2015).  
The guidelines applicable to products intended for zero-day tissue withdrawal require only one 
time-point with 6 animals at the time point between 3- and 12-hours following withdrawal.  This 
constitutes zero-withdrawal.  The zero-day tissue withdrawal intent were based on the cattle 
study (Chapter 4) where no residues were detected in any tissue following 12 hours 
withdrawal. 
An additional 24 hours withdrawal point were included in the trial design to evaluate residue 
depletion should any residues be detected at the 7 hours withdrawal time point. 
Group A, consisting out of 1 animal, did not receive R-salbutamol and was slaughtered after 
the acclimation period as negative control (study day +1).  Group B and C, consisting out of 
six animals each receiving R-salbutamol, were slaughtered at 7 hours and 24 hours after 
withdrawal of R-salbutamol medicated feed, respectively.  The carcasses of Group B and C 
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were disposed of at the abattoir and were not intended for human consumption.  The control 
animal (group A) entered the food chain.  No animals were removed after inclusion in the 
study. 
The R-salbutamol medicated feed of groups B and C were removed on the morning of day 29 
at 7 hours and 24 hours before slaughter, respectively. The feeding troughs were cleaned, 
and all the animals received non-medicated feed without R-salbutamol for the remainder of 
the period until they were slaughtered. 
Slaughter schedule: 
 Day 1 one control animal from Group A. 
 Day +29 Group B animals (n=6) (7:38 – 7:58 hours (<12 hours) after last R-
salbutamol consumption) 
 Day +30 Group C animals (n=6) (24:47 – 24:58 hours (24 ± 2 hours) after last R-
salbutamol consumption) 
Specimens of muscle, kidney, liver and renal fat were collected at slaughter for determination 
of R-salbutamol residue levels.  
3.2.8 Body weight (BWt) 
The animals were weighed during acclimatization on study day -6 for the purposes of inclusion 
and allocation to study groups and again on the morning of R-salbutamol withdrawal (study 
day +29) to be able to determine the average mg /kg BWt intake of R-salbutamol.  
3.2.9 Organ sampling for residue analysis 
Specimens of the muscle, kidney, liver and renal fat were collected for determination of R- 
salbutamol concentrations on day +29 (7 hours withdrawal) and day +30 (24 hours 
withdrawal). The samples taken from the control animal slaughtered at the start of the 
medicated feed period (day +1) were used as the negative control during laboratory analysis 
to ensure that the method used for analysis were accurate for the determination of R-
salbutamol in animal tissue.  Negative control tissue samples were also used to spike samples 
in the lab to a known amount to determine accuracy of laboratory results. 
Duplicate specimens of approximately 250 gram or as much as is physically possible, of 
muscle, kidney, liver and renal fat were collected from each animal.  Extreme care was taken 
to avoid contamination of the tissues. Separate knives were used for each animal and the 
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operator(s) took precautions to remove any contaminated clothing and washed their hands 
between sampling of each animal.    
If an organ became contaminated by touching another collected organ, the outside of both 
organs was washed under running potable water. Collected organ specimens were placed in 
labelled freezer bags of suitable size and sealed air tight at the time of slaughter. Labels 
indicate the tissue specimen, animal ID, study group, date of collection, collection time and 
the study number. Organ specimens were kept cool in polystyrene containers with ice and 
frozen within 24 hours after collection at <-20°C.  All organ specimens were dispatched to the 
analytical laboratory (ARC OVI Residue Laboratory, Pretoria) after the last sample collections. 
Liver, muscle, kidney and fat samples of Test Group A, B and C were analysed for parent and 
total (parent + metabolites) salbutamol residues. 
3.2.10 Analytical Method 
Samples were analysed at the Agricultural Research Council (ARC) Residue Laboratory at 
Onderstepoort Veterinary Institute (OVI).  Method validation was performed to demonstrate 
that the LC-MS/MS method was fit-for-purpose in the identification of R-salbutamol in animal 
tissue. 
The correlation coefficient for the calibration curve of all tissues were >0.99. 
Racemic Salbutamol was purchased from Sigma Aldrich (Lot # SZB9016XV, 99.8% purity). 
HPLC grade solvents (Ammonium formate, Methanol (MeOH), trichloracetic acid (TCA) 
Acetonitrile (ACN), β-glucoronidase) were supplied by Riedel-de Haën and Sigma Aldrich. 
HPLC-grade H2O were obtained from an Elgastat UHQ water purifier system. 
Solutions were made as follow: 
o 1M Ammonium formate (dissolve 6.408 g in 100 ml H2O)
o 5mM Ammonium formate (5 ml of 1M ammonium acetate to 1000ml of H2O or MeOH)
A Kinetex 2.6μ PFP 100 Å, 50 x 2.10 mm, analytical column was used during the analysis. 
Ultra High Performance Liquid Chromatograph (UPLC) analysis was performed using a 
Shimadzu Nexera X2 analyser and mass spectrometry (MS) was performed using an ABSciex 
Triple quadruple mass spectrometer. 
Aliquots of 5 ± 0.1 g of liver, muscle and kidney, and 1 ± 0.1 g of fat were placed in 
homogeniser tubes together with three blank samples and 7 spiked samples at 0.5, 1, 2, 5, 
10, 20 and 50 ppb.  Spiked samples were then vortexed for 30 seconds.  Acetate buffer (1M, 
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200 μL, pH 5.2) together with 3.8 ml dH2O was then added to the samples and tissue was 
homogenised for approximately 1.5 min. For the total residue detection method 50 μL β-
glucoronidase was added to the sample, gently mixed and incubated at 37°C for 3 hours. For 
the samples analysed for parent salbutamol this step was omitted. 
TCA 10% (100 μL) and ACN (10 ml) containing 1% (v/v) acetic acid were then added and 
vortexed. Thereafter, 4 g MgSO4 and 1 g NaCl were added and thoroughly mixed for 1 min on 
the vortex. The samples were then frozen at this point at -20°C for 2 hours. Samples were 
then centrifuged at 9500 g for 10 min, ensuring the centrifuge remained at 4°C.   
A total of 5 ml of the content of the tube was then transferred to a 50 ml tube containing 150 
mg C18 and vortexed. The sample was centrifuged again at 9500 g for 10 min at approximately 
4°C. The remaining fluid was carefully decanted into a test tube and dried completely at 50°C. 
The dried extract was then reconstituted with 300 μL 50% MeOH followed by filtration through 
0.22 μM PTFE filters. The solution was transferred to a vial and injected on the LC-MS auto-
sampler. 
The Limit of Quantification (LOQ) for this method was determined to be 0.5 µg/kg. 
3.2.11 Statistical Analysis 
A primary statistical method to determine the withdrawal period from each of the body tissues 
is described in the guidelines on MRL’s and Withdrawal Periods by the Medicines Control 
Council of South Africa (MCC) (MCC, 2004). 
The protocol describes the conventional statistical methods based on a regression analysis to 
be applied for the determination of withdrawal periods.  However, as two time points with six 
animals each were chosen as the design for the residue trial, as described in the MCC 
guidelines for zero withdrawal, no regression analysis was possible.  The alternative method 
to determine the withdrawal period, as set out in the MCC guidelines, is to set the withdrawal 
period at the time point where the calculated Theoretical Maximum Daily Intake (TMDI) is 
below the Acceptable Daily Intake (ADI). 
To calculate the TMDI, the average residue in each tissue (i.e. liver, muscle, kidney and fat), 
as determined at each withdrawal time point, is used and added to the product of the standard 
deviation (SD) multiplied with the food consumption factor (CF).  The CF was described by 
the Joint FAO/WHO Expert Committee on Food Additives (JECFA) in their 34th report entitled 
“Evaluation of Certain Veterinary Drug Residues in Food” (JECFA, 1989).   
The consumption factor for each tissue type is summarised in Table 3.2. 
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Table 3.2: Food Consumption Factors for each tissue type as defined by JECFA 
Tissue Daily Intake 
Muscle 300 g 
Liver 100 g 
Kidney 50 g 
Fat 50 g 
A one-sided upper tolerance limit or upper confidence limit (UCL) is then calculated by adding 
the calculated theoretical intake of residues in the animal tissue and adding the product of the 
standard deviation (SD) with the g™ factor. 
𝑈𝐶𝐿 = 𝑚𝑒𝑎𝑛 +  (𝑔™ × 𝑆𝐷) 
Where: 
g™ = A factor for calculating a one-sided tolerance estimate of conformance with a given 
threshold and confidence level.  
The g™ factor is based on the number of animals used at each time point in the residue kinetic 
study and the accepted statistical significance of the data as well as the statistical confidence. 
MCC has accepted the use of a 95% statistical significance with a 90% statistical confidence 
(MCC, 2004). The table with the relevant g™ factors is published in the MCC guidelines on 
MRL’s and Withdrawal Periods (MCC, 2004).  
Using the sample size (N = 6) in this trial at each time point, the g™ parameter applicable for 
this trial equals 3.066. 
All data is reported as the average ± standard error of the mean (SEM) unless otherwise 
indicated. 
3.3 Results and Discussion 
As the feed used in the trial was spiked twice daily with the test item it had to be confirmed 
that the initial feed was free from R-salbutamol or any other β-AA. Feed was tested for R-
salbutamol and zilpaterol and it was confirmed that the feed did not contain any beta-agonist. 
The average body weight at the start of the trial (day -6) was 42.53 ± 1.14 kg and at the end 
of the trial (day +29) 48.72 ± 1.61 kg.  The ADG for all animals in the trial was only 162 g/day, 
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which would be expected to be much lower than normal feedlot performance of 300 - 350 
g/day, as animals were not fed ad lib. 
There were no R-salbutamol related physical signs (tremors and restlessness) recorded 
during daily general health observations of animals in this study. Horses fed zilpaterol at 0.17 
mg/kg BWt showed signs of profuse sweating, skeletal muscle tremors and restlessness 20 
to 25 minutes after ingesting zilpaterol. These symptoms continued for a week following the 
zilpaterol ingestion (Wagner, Morstrom, Hammer, Thorson, & Smith, 2008).  
Nasal discharge, that was observed in 2 of the 12 lambs at the start of the trial (day -6 to -4), 
and again at day 16, was associated with apparent ovine respiratory disease, as diagnosed 
by a veterinarian, and not considered to be related to R-salbutamol treatment. 
Ocular discharge and depressed behaviour were observed in 6 of the 12 lambs from day -6 to 
-2, and again from day 11 to 28.  This was diagnosed as infectious keratoconjunctivitis  
by a veterinarian. 
The nasal discharge, depressed behaviour and ocular discharge can possibly be attributed to 
lower respiratory tract infection, caused by viruses, bacteria, or parasites (Scott, 2018) 
Heart rate, respiratory rate and rectal temperature was measured at day -1 and Day 28 of the 
trial. There was no difference (P > 0.05) in the heart rate of the lambs measured at day -1 
(111.83 ± 4.39 bpm) and day 29 (114.83 ± 3.79 bpm).  This data is in alignment with the 
observations of Marchant-Forde et al. (2008) where no effect was observed on the heart rate 
of pigs fed different levels of R-salbutamol.  Similar observations were made in 2 unpublished 
trials performed in Australia by the developers of R-salbutamol for production animal use 
(Chambers, 2007a, b).   
This is in contrast with the effect on heart rate that was observed with the supplementation of 
various other longer acting beta-agonists in cattle, lambs, goats and pigs.  Mersmann (1987) 
reported an increase in heart rate in pigs of between 36% and 83% for isoproterenol, 15% to 
43% for dobutamine, and 43% to 46% for terbutaline.  The increase of heart rate was dose 
related for all β-AA’s used in these studies.  Increased heart rate (P ≤ 0.05) was also observed 
in cattle fed ractopamine and zilpaterol (Frese, 2015) and a similar effect on the increase in 
heart rate (P ≤ 0.05) was observed in lambs fed cimaterol (Beerman, Hogue, Fishell, 
Dalrymple, & Ricks, 1986) and goats fed zilpaterol (Hatefi, et al., 2017). 
Differences (P ≤ 0.05) were however observed in the respiratory rate and rectal temperature 
of lambs between day -1 and day 28.  Rectal temperature increased from 38.97 ± 0.07°C (day 
-1) to 39.5 ± 0.16°C (day 28). Normal rectal temperature in lambs is between 38.3°C and 
Stellenbosch University  https://scholar.sun.ac.za
63 
39.9°C (Fielder, 2018a), therefore the measurements were within the normal range and not 
clinically significant. 
The respiratory rate also increased from 47.92 ± 5.01 (day -1) to 81.33 ± 9.55 (day 28) breaths 
per minute after inclusion of R-salbutamol.  Normal respiratory rate in lambs is between 16 
and 34 breaths per minute (Fielder, 2018b).  The respiratory rate on day -1 was slightly higher 
than normal, but respiratory rate at day 28 could be classified as hyperventilation.  
Environmental temperature was not recorded. 
The increase in respiratory rate was observed in 7 of the 12 lambs of which 6 of the 7 lambs 
showed clinical signs of possible lower respiratory tract infection.  Increased respiratory rate 
is one of the clinical signs of lower respiratory tract infection and commonly affect sheep (Scott, 
2018). 
The 7 lambs with increased respiratory rate had an average respiratory rate of 106.14 ± 5.38 
at day 28 in comparison to the remaining 5 lambs with a respiratory rate of 43.5 ± 5.03 breaths 
per minute.  The increase in respiratory rate could therefore be attributed to the lower 
respiratory tract infection rather than the use of R-salbutamol. 
An increase in respiratory rate, attributed to the use of β-AA, was observed in previous studies 
with the use of zilpaterol in cattle (Boyd, et al., 2015; Hales, et al., 2014) and goats (Hatefi, et 
al., 2017), as well as with the use of clenbuterol in milk replacer calves (Blum & Flueckiger, 
1988). 
Many studies have been performed where the total salbutamol residue (parent + metabolised 
salbutamol) is the target residue for detection.  These analysis methods include hydrolyses of 
the sample with β-glucoronidase enzyme (in animal tissue) to extract the metabolised 
salbutamol fraction and report total salbutamol residues (parent + metabolites) in the target 
tissue.  These methods are however developed to assist in determining the illegal use of beta-
agonists in countries were their use is not approved (Chang, Chang, & Tsai, 2018; Montes 
Nino, et al., 2017; Yi-Po, et al., 2016). 
Parent salbutamol was tested as the marker residue in the present investigation.  As R-
salbutamol is metabolised through glucuronide conjugation in animals and the metabolite is 
not active (Martin, Hobson, Page, & Harrision, 1971), the parent salbutamol fraction is 
considered for residue detection and is the marker residue for residue analysis.  This is in 
accordance with the marker residues accepted for both zilpaterol (EFSA, 2016) and 
ractopamine (EFSA, 2009).  However, to better understand the metabolism and excretion of 
R-salbutamol in this study, the analysis method was repeated on each sample with the 
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additional hydrolysis step to enable detection of total salbutamol residue (parent + metabolised 
salbutamol).  
Table 3. summarises the parent salbutamol residue levels as determined for all tissue of 
animals slaughtered at the 7 hour and 24-hour time point as well as the negative control 
animal.     
Table 3.3: Mean concentration (± standard deviation) of parent salbutamol in the tissue of lambs 
Study Day Group 
Parent salbutamol (μg/kg in tissue) ± Standard Deviation 
Muscle Kidney Liver Fat 
+1 A (Control) <LOQ* <LOQ <LOQ <LOQ 
+29 B (7hrs) 0.79 ± 0.80** 6.32 ± 3.78 75.80 ± 23.18 2.03 ± 1.38 
+30 C (24hrs) 0.44 ± 0.47*** 2.73 ± 1.78 33.82 ± 12.56 0.98 ± 1.20**** 
*LOQ = limit of quantification (0.50 μg/kg tissue)
** 3 of 6 samples tested <LOQ
*** 5 of 6 samples tested <LOQ
**** 2 of 6 samples tested <LOQ
Where the analysed value is below the LOQ (0.50 μg/kg) the value is taken as half the LOQ 
(0.25 μg/kg) to determine the average and standard deviation as per the MCC guidelines 
(2004) and the International Cooperation on Harmonisation of Technical Requirements for 
Registration of Veterinary Medicinal Products (VICH) (VICH, 2015). 
At both time points, the highest average residues of parent salbutamol in tissue were detected 
in the liver (85.4 - 93.7% after 7 hours and 83.2 - 94.2% after 24 hours withdrawal) followed 
by the kidney (4.7 – 10.4% after 7 hours and 0.8 – 12.7% after 24 hours withdrawal).  Muscle 
had 0.3 - 2.4% after 7 hours and 0.4 – 4.3% after 24 hours withdrawal of all residues and fat 
had 1.3 – 3.8% after 7 hours and 0.6 – 5.1% after 24 hours withdrawal.  Variation did occur 
between animals with regards to the distribution of percentage of total parent salbutamol in 
tissue but in all instances, liver had by far the highest residue level followed by kidney. 
Variation also occurred between animals at both time points with regards to whether fat or 
muscle tissue had the highest residue levels.   
Three of the 6 muscle samples had no detectable residues at 7 hours after withdrawal, while 
5 of the 6 samples at 24 hours after withdrawal had no detectable residues of parent 
salbutamol.  All fat samples had detectable residue levels of parent salbutamol after 7 hours 
withdrawal, and two fat samples were below the LOQ after 24 hours withdrawal.  
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To determine the total fraction of parent salbutamol together with the major metabolite, 
samples were hydrolysed with β-glucoronidase as an additional step in the extraction as 
described in section 3.2.10.  The total salbutamol for all 4 tissues is summarised in Table 3.3. 
Table 3.3: Mean concentration (± standard deviation) of total salbutamol (parent + metabolite) in the 
tissue of lambs 
Study 
Day 
Group 
Total salbutamol (μg/kg) ± Standard Deviation 
Muscle Kidney Liver Fat 
+1 A (Control) <LOQ* <LOQ <LOQ <LOQ 
+29 B (7hrs) 3.33 ± 2.66 15.93 ± 16.01 181.27 ± 74.8 19.03 ± 9.49 
+30 C (24hrs) 2.62 ± 0.52 8.58 ± 3.62 91.31 ± 37.76 6.58 ± 7.18 
*LOQ = limit of quantification (0.50 μg/kg tissue)
At 7 hours after withdrawal of R-salbutamol in feed, 41.8% of the total residues was present 
as parent salbutamol in the liver compared to total salbutamol (75.8 μg/kg parent salbutamol 
vs. 181.27 μg/kg total salbutamol).  At 24 hours after withdrawal the amount of parent 
salbutamol reduced slightly to 37.0% of total salbutamol in the liver (33.82 μg/kg parent 
salbutamol vs. 91.32 μg/kg total salbutamol). The average total salbutamol at 24 hours after 
withdrawal (91.32 μg/kg total salbutamol) was however reduced to 50% of that detected at 7 
hours after withdrawal (181.27 μg/kg total salbutamol) in the liver. 
Less parent salbutamol was detected in the kidney as a proportion of total salbutamol at both 
withdrawal time points with 39.6%, and 31.7% of parent salbutamol as a percentage of total 
salbutamol detected at 7 hours (6.32 μg/kg parent salbutamol vs. 15.93 μg/kg total salbutamol) 
and 24 hours (2.73 μg/kg parent salbutamol vs. 8.58 μg/kg total salbutamol) respectively. The 
average total salbutamol at 24 hours after withdrawal (8.58 μg/kg total salbutamol) was also 
reduced to almost half (54%) of that detected at 7 hours after withdrawal (15.93 μg/kg total 
salbutamol) in the kidney. 
Muscle had 23.8% parent salbutamol as a percentage of total salbutamol at 7 hours after 
withdrawal (0.79 μg/kg parent salbutamol vs. 3.33 μg/kg total salbutamol), but the percentage 
dropped to 16.9% after 24 hours withdrawal (0.44 μg/kg parent salbutamol vs. 2.62 μg/kg total 
salbutamol).  The average total salbutamol at 24 hours following withdrawal (2.62 μg/kg total 
salbutamol) was 78.5% of the total salbutamol detected at 7 hours after withdrawal (3.33 μg/kg 
total salbutamol) in the muscle, but at very low levels as indicated in Table 3.3. 
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The concentration of total salbutamol declined more rapidly in fat than in any other tissue with 
only 34.6% of total salbutamol still present at 24 hours (6.58 μg/kg total salbutamol) after 
withdrawal in comparison to the levels at 7 hours after withdrawal (19.03 μg/kg total 
salbutamol).  Parent salbutamol were the lowest as a percentage of total salbutamol in fat with 
10.7% of total salbutamol present as parent salbutamol at 7 hours after withdrawal (2.03 μg/kg 
parent salbutamol vs. 19.03 μg/kg total salbutamol) and 14.9% of total salbutamol present as 
parent salbutamol at 24 hours after withdrawal (0.98 μg/kg parent salbutamol vs. 6.58 μg/kg 
total salbutamol). 
As the MRL has not been set for R-salbutamol, the trial data can be used to determine a TMDI 
according to the MCC guidelines (MCC, 2004) from which a MRL can be derived.  The formula 
is described in detail in section 3.2.11. The UCL is determined for each tissue type by adding 
the product of the SD with the g™ factor.  Table 3.5 describes the calculation for the UCL at 
7 hours following withdrawal and Table 3.6 describes the calculations for the UCL at 24 hours 
withdrawal.  The UCL for each tissue type is then multiplied by the relevant consumption factor 
to determine the TMDI (Table 3.7).  
Table 3.5: UCL for parent salbutamol in liver, kidney, muscle and fat at 7-hours withdrawal 
Muscle Liver Kidney Fat 
Average Residue (μg/kg) 0.79 75.80 6.32 2.03 
SD 0.80 23.18 3.78 1.38 
g™ (90/95) 3.066 3.066 3.066 3.066 
UCL (90/95) (μg/kg) 3.25 146.87 17.91 6.25 
Table 3.6: UCL for parent salbutamol in liver, kidney, muscle and fat at 24-hours withdrawal 
Muscle Liver Kidney Fat 
Average Residue (μg/kg) 0.44 33.82 2.73 0.98 
SD 0.47 12.56 1.78 1.20 
g™ (90/95) 3.066 3.066 3.066 3.066 
UCL (90/95) (μg/kg) 1.88 72.33 8.19 4.66 
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Table 3.7: Theoretical Maximum Daily intake calculated from parent salbutamol UCL in each tissue type 
at 7- and 24-hours following withdrawal 
Time 
UCL (90/95) (μg/kg) 
Average intake after Consumption 
Factor (CF) is applied (μg) 
TMDI 
(μg/person) 
Muscle Liver Kidney Fat 
Muscle 
(CF = 
300g) 
Liver 
(CF = 
100g) 
Kidney 
(CF = 
50g) 
Fat 
(CF = 
50g) 
7 hrs 3.25 146.87 17.91 6.25 0.98 14.69 0.90 0.31 16.88 
24 hrs 1.88 72.33 8.19 4.66 0.56 7.23 0.41 0.23 8.43 
Figure 3.1 below illustrates the the calculated TMDI in comparison with the ADI 
(µg/person/day).   
Figure 3.1: TMDI calculated for parent salbutamol in lambs 
The withdrawal period is set at the time point where the TMDI is below the ADI.  The TMDI for 
salbutamol is far below the ADI at both time points (Figure 3.1). The TMDI is 9.38% of the ADI 
at 7 hours and 4.68% of the ADI at 24 hours after withdrawal. 
Similar calculations with residue data on zilpaterol in lambs (0.15 mg zilpaterol/kg BWt) 
indicated a TMDI at day zero of 462% of the ADI, 206% at day 2 and 22.9% at day 5.  The 
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TMDI were equal to ADI at day 4 of the zilpaterol treatment.  Also, a half-life for zilpaterol of 
15.3 ± 1.8 hours were calculated for zilpaterol in lambs using urinary excretion values. 
According to pharmacological theory, this would indicate that all residues will be excreted from 
the lambs’ body by 6.25 days (half-life x 10), although residues were still detected after 9 days 
in the lambs’ liver, muscle and kidney.  Day 0 to 5 residue excretion followed a linear trend, 
but the day 9 residue levels were slightly higher than the day 5 values (Shelver & Smith, D.J., 
2006) 
When the data from Shelver and Smith (2006) is compared to the published MRL for zilpaterol 
(EFSA, 2016), the liver and kidney values are below the MRL at 2 days of withdrawal.  The 
residue in meat is only below the published MRL following 5 days of withdrawal.   
Although a half-life has not been determined for R-salbutamol in lambs, the half-life in humans 
for R-salbutamol is calculated to be 2.00 ± 0.49 hours (Boulton & Fawcett, 1996b).  If the half-
life is similar in lambs this will indicate that all residues should be excreted from the body by 
20 hours.  Parent salbutamol residues are still detected beyond this point (Table 3.), although 
very low, which could indicate that residual and active R-salbutamol may still be absorbed 
from the gastro intestinal tract following withdrawal.  
The TMDI is used as the starting point for proposing a MRL for any molecule used in food 
producing animals.  The published MRL for Zilpaterol, when applying the food consumption 
factors, equates to 27.7% of the ADI for an adult human and that of Ractopamine equates to 
20% of the ADI for an adult human. 
The MRL for R-salbutamol is therefore suggested to be set for liver at 300 µg/kg, muscle at 
6.5 µg/kg, kidney at 40 µg/kg and fat at 13 µg/kg. At these levels the daily intake of residue 
will still be below 20% of the ADI. 
3.4 Conclusion 
R-salbutamol has no visual adverse effects on animals consuming the medicated feed and 
therefore R-salbutamol use in feedlot production can be confirmed to be safe for the target 
animal.  Although the increase in rectal temperature were not clinically significant and the 
increase in respiratory rate could be attributed to lower respiratory infection, the effect of R-
salbutamol use on rectal temperature and respiratory rate should be further investigated.    
Salbutamol residues in ovine tissue fed R-salbutamol in their ration for 28 days, showed a 
rapid decline in residue levels from 7 hours after withdrawal to 24 hours after withdrawal.  The 
TMDI calculated based on the residue levels detected, indicated that salbutamol residues 
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present in animal tissue following 7 hours withdrawal is far below the safe intake level/ADI 
calculated in humans.  According to the MCC guidelines (MCC, 2004), any study determining 
a withdrawal period of less than 12 hours is considered to be equivalent to zero withdrawal. 
The withdrawal period for R-salbutamol in lambs can therefore be set at zero with confidence 
that ingestion of tissue from lambs fed R-salbutamol at the recommended dosage levels will 
provide adequate consumer protection. 
At the determined UCL for the individual tissue, the intake level in animal tissue is far below 
the safe level/ADI in humans.  Should the individual tissue contain the above UCL levels, 
humans will have to consume over 55 kg of meat, 1.2 kg liver, 10 kg of kidney or 28.8 kg of 
fat to have an intake equal to the safe level of R-salbutamol in humans, where no adverse 
events will be observed.  For any acute pharmacological adverse event to occur, the tissue 
intake would have to be more than 10 times the ADI to have any possible acute effect in 
humans. Animal tissue derived from feedlot lambs fed R-salbutamol at the recommended 
inclusion level, with no withdrawal, is therefore deemed safe for human consumption. 
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CHAPTER 4 
R-SALBUTAMOL RESIDUE DEPLETION STUDY IN FEEDLOT CATTLE 
ABSTRACT 
This study investigated the residue and target animal tolerance of R-salbutamol in feedlot 
cattle. One group of four cattle received non-medicated feed as the control group A. Three 
groups each of six cattle received 150 mg R-salbutamol/head/day (0.42 mg/kg BWt) in feed 
for 44 days (group B, C and D). One animal from the control group was slaughtered on 
study day 3.  Group B, C and D was slaughtered on <12-, 24- and 48-hours following 
withdrawal of R-salbutamol from feed respectively together with one each of the control 
group. The control animals were included to show that there were no residues occurring 
naturally within the test flock. Liver, kidney, muscle and fat samples were collected and 
analysed for salbutamol residues (HPLC-DAD). No residues were detected for total 
salbutamol (LOQ = 3 μg/kg) in any of the tissues except for one muscle sample at 48 hours 
withdrawal (37 μg/kg). This result was disregarded and viewed as an analytical anomaly. 
No visual adverse events were observed in the study animals and R-salbutamol was well 
tolerated in cattle.    
4.1 Introduction 
An ever-increasing demand for food production to feed a growing world population has led 
researchers to develop technologies to improve animal growth efficiency and subsequent 
increase in meat production from the limited land and water resources (Capper & Hayes, 2012; 
UNPD, 2007).  These technologies have not been accepted by everyone as the solution to 
the increased food demand. The withdrawal of antibiotics in the European Union (EU) 
(European Commission, 2005) and pressure on the use of hormonal growth implants (Doyle, 
2000) are but a few examples of technology under scrutiny by regulators and the consumers. 
Beta-adrenergic agonists (β-AA) have not been spared criticism and have been banned for 
use in food producing animals in 160 countries including the EU (Kerr & Hobbs, 2005) and 
China (Meador & Wu, 2011).   
The reported cases (Barbosa, et al., 2005; Brambilla, et al., 1997; Maistro, Chiesa, Angeletti, 
& Brambilla, 1995; Pulce, Lamaison, Keck, Bostvironnois, & Nicolas, 1991; Salleras, 
Dominquez, Taberner, Moro, & Salva, 1995; Shiu & Chong, 2001) of clenbuterol related food 
poisoning due to consumption of animal tissue from animals illegally fed clenbuterol as 
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productivity enhancer has placed a negative light on the value of β-AA as a safe technology 
in the quest to improve food supply. 
In August 2013 Tyson Foods Inc., the second largest processor and marketer of chicken, pork 
and beef in the world, announced that they will not buy any cattle fed Zilmax (zilpaterol 
hydrochloride, MSD Animal Health) stating their concerns with regards to the welfare of cattle 
fed zilpaterol (Reuters, 2013).  Subsequently MSD Animal Health (formerly known as Merck 
Animal Health) suspended the sale of Zilmax in the United States (US) market (American 
Veterinary Medical Foundation, 2013).  The impact on the withdrawal of Zilmax from the US 
market was estimated to lead to a reduction in meat production of 6% (Vance, 2013). 
The evaluation of these technologies on the impact on animal welfare, as well as consumer 
safety is therefore of utmost importance. The Joint FAO/WHO Expert Committee on Food 
Additives (JECFA) has however evaluated the safety and use of zilpaterol and ractopamine 
and found it to be safe if used according to the prescribed dosing regime and adhering to 
correct withdrawal periods (EFSA, 2009; EFSA, 2016). 
Prior to the registration of Salbutamate 10% (R-salbutamol sulphate, Animate Animal Health) 
for use in cattle, a residue study is required to determine the residue kinetics of R-salbutamol 
in beef cattle as well as the target animal safety. The growth efficiency of the animals in the 
trial were not of concern as feed intake was restricted and the animals would therefore not 
perform as expected in a normal growth efficiency trial. 
4.2 Materials and Methods 
The research project was approved by the Clinvet Animal Ethics Committee (AEC: CV09/665) 
and handling and housing of all animals were conducted according to the South African 
National Standards 10386: 2008. 
The trial was conducted at ClinVet International (Pty) Ltd (Bainsvlei, Free State, South Africa). 
4.2.1 Animals 
The animals used in this study were feedlot type cattle (gender not specified) ranging in weight 
from 340 kg to 385 kg at arrival. Animals were purchased from Sparta Beef, Marquard, Free 
State.   
Twenty-two cattle were randomly allocated to one of four groups according to a randomised, 
parallel group design.  The individual bovine was the experimental unit in this study.    
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4.2.2 Housing 
Animals were housed individually in indoor stable units with outside paddocks.  Stables were 
not environmentally controlled and environmental conditions fluctuated with ambient 
conditions.   
The identification number of the bovine housed inside a stable, the study number, study group 
brand of feed and feed quantity were indicated on the outside of each stable.  The size of each 
indoor stable was 7.5 m2 and the size of the outside paddock was 115.2 m2 on the north-east 
and south-east aspect and 98.4 m2 on the north-west and south-west aspect of the facility 
respectively. 
Routine practices were standardised across all animals.  All cattle were at the study facility for 
14 days prior to the start of R-salbutamol administration. 
4.2.3 Feed and water 
The cattle purchased was already processed and fed a grower ration at the feedlot.  Therefore, 
feed acclimatisation was not required once they arrived at the trial facility.   
A balanced, commercial cattle feedlot grower ration, sourced from Nutrifeeds, Bloemfontein, 
Free State was fed (Table 4.).   
Table 4.1: Nutrient composition of cattle feedlot finisher ration 
Nutrient Quantity (g/kg) 
Protein 140.3 
Fat 71.4 
Ash 50.9 
NDF 210.5 
ADF 67.5 
Moisture 128.1 
Calcium 6.5 
Phosphorus 4.8 
Feed intake was restricted during the trial to ensure that cattle consumed their allocated 150 
mg R-salbutamol per day. Cattle were fed three times a day and each feed were spiked with 
50 mg R-salbutamol during the medicated period. Animal behaviour associated with feeding 
was observed through the day and the allocated amount of feed was adjusted if it became 
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clear that feed intake requirements increased.  Feed and free access to potable water was 
supplied in plastic and rubber troughs on the floor.  
A 250 g specimen of each batch of feed was collected and analysed to confirm that no levels 
of R-salbutamol were present in the feed. 
4.2.4 Experimental Procedure 
One group of four cattle received non-medicated feed as the control group A. Three groups 
(group B, C and D) each of six cattle received R-salbutamol in feed three times a day for 44 
days.  
All the animals received feed without R-salbutamol during the 14-day non-medicated phase 
prior to the 44-day medicated (R-salbutamol) phase. During the non-medicated phase, feed 
was supplied in excess and the intake of individual cattle were determined. This was done to 
ensure that all feed allocated and medicated each day were consumed. If any feed was 
leftover, the feed was weighed in the afternoon and the next days feed allocation was adjusted 
accordingly.  From day +1 group B, C and D was fed 1.5 g of Salbutamate 10%, equivalent to 
150 mg R-salbutamol per animal per day (± 0.42 mg/kg body weight (BWt) at start weight), in 
feed daily for 44 consecutive days while the control group (group A) received non-medicated 
feed. The 44 days of treatment was equivalent to the period in commercial feedlots prior to 
marketing, referred to as the finishing stage before slaughter. 
R-salbutamol was administered as a feed additive, as it is marketed and sold as a feed additive 
for feedlot cattle. R-salbutamol was used at the intended dose, dosage frequency and duration 
required to imitate the cattle feedlot situation. 
Personnel wore overcoats, impervious gloves and a dust mask during administration of R-
salbutamol. 
4.2.5 Animal handling 
The cattle were handled by personnel in a cattle crush during clinical examination and were 
loaded on a truck for transport to the local abattoir at the end of this study. No other forms of 
restraint were applied.   
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4.2.6 Animal Observations 
General health observations were performed daily throughout the study. The aim of the 
general heath observation was to detect any health issues that may warrant veterinary care 
or constitute withdrawal of animals from the study. These observations included, but were not 
limited to, habitus, appetite, colour of urine, colour and consistency of faeces, salivation, 
vomiting, skin lesions and any obvious change in general condition.  
Clinical examinations were performed once during the non-medicated phase on day -11 of the 
study. These examinations included, but were not limited to, body condition, vital signs (heart 
rate, respiratory rate and rectal temperature), mucous membranes, eyes, motility, thoracic 
auscultation and skin condition.  The aim of the clinical examination was to determine if all 
animals were healthy and suitable to be included in the study. 
The intent of the trial was to determine the residue kinetics of R-salbutamol in cattle.  Clinical 
examination following the start of the trial was not repeated as it is not required by VICH 
guideline GL48 (Studies to evaluate the metabolism and residue kinetics of veterinary drugs 
in food-producing animals: Marker residue depletion studies to establish product withdrawal 
periods) (VICH, 2015). 
4.2.7 Body weight 
The animals were weighed once during the non-medicated feeding period on day -11 of the 
study, with the weights being rounded up to the next 5 kilograms. Cattle were not weighed at 
the end of the study as the intent of the study was to determine the residue kinetics of R-
salbutamol in cattle and growth would be restricted due to restricted feeding. 
4.2.8 Feed withdrawal and slaughter schedule 
The trial design was based on the VICH guideline GL48 (Studies to evaluate the metabolism 
and residue kinetics of veterinary drugs in food-producing animals: Marker residue depletion 
studies to establish product withdrawal periods). A minimum of four animals is required per 
time point and a minimum of three time points to allow for regression analysis. Higher number 
of animals per time point will improve statistical analysis to improve determination of the 
withdrawal period (VICH, 2015). 
Group B, C and D, consisting of six animals each receiving R-salbutamol, were slaughtered 
at 12, 24 and 48 hours after withdrawal of R-salbutamol medicated feed, respectively. The 
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feeding troughs were cleaned, and all the animals received feed without R-salbutamol for the 
remainder of the study. The slaughter schedule is summarised in Table 4.2. 
Table 4.2: Slaughter schedule applied to the cattle fed R-salbutamol or none 
Study day Description 
3 one control animal from Group A 
+45 
Group B animals (n = 6) plus 1 control animal (group A) (11 hours 34 minutes to 11 
hours 51 minutes (<12 hours) after last R-salbutamol consumption) 
+46 
Group C animals (n = 6) plus 1 control animal (group A) (22 hours 57 min to 23 
hours 06 minutes (24 ± 2) last R-salbutamol consumption) 
+30 
Group D animals (n = 6) plus 1 control animal (group A) (46 hours 30 minutes to 46 
hours 39 min (48 ± 2 hours) last R-salbutamol consumption) 
4.2.9 Organ sampling for residue analysis 
Specimens of the muscle, kidney, liver and renal fat were collected for determination of R-
salbutamol concentrations on study days +3, +45 (<12 hours withdrawal), +46 (24 hours 
withdrawal) and +47 (48 hours withdrawal). Negative control tissue samples were also used 
to spike samples in the lab to a known amount to determine accuracy of laboratory results. 
Duplicate specimens of approximately 250 g or as much as physically possible, of muscle, 
kidney, liver and renal fat were collected from each animal.  Extreme care was taken to avoid 
contamination of the tissues.  Separate knives were used for each animal and the operator(s) 
took precautions to remove any contaminated clothing and to wash hands between sampling 
of each animals.    
If an organ became contaminated by touching another collected organ, the outside of both 
organs was washed under running potable water. Collected organ specimens were placed in 
labelled freezer bags of suitable size and sealed air tight at the time of slaughter. Labels 
indicate the tissue specimen, animal ID, study group, date of collection, collection time and 
the study number. Organ specimens were kept cool in polystyrene containers with ice and 
frozen within 24 hours after collection at -20°C or lower.   All organ specimens were dispatched 
to the analytical laboratory (ARC OVI Residue Laboratory, Pretoria) after collection on day 
+46. 
Liver, muscle, kidney and fat samples of Test Group A, B, C and D were analysed for total 
(parent + metabolites) salbutamol residues. 
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4.2.10 Laboratory method 
The analysis of salbutamol in tissue was performed at the Onderstepoort Veterinary Institute, 
Residue Laboratory.  The laboratory is the official laboratory in South Africa for residue 
monitoring of, among other, β-AA in animal tissue.  The laboratory was the only laboratory in 
South Africa able to analyse animal tissue for salbutamol residues.  At the time of the trial, the 
method applied for detection of all β-AA residues in animal tissue at the Residue Laboratory 
was high performance liquid chromatography (HPLC) method with a diode array detector 
(DAD). 
The HPLC-DAD method for the assay of the salbutamol enantiomers in bovine liver and kidney 
was based on an enzymatic hydrolyses followed by an anion exchange clean-up. For bovine 
fat the method was based on extraction with tetrachloroethylene, liquid-liquid extraction with 
a potassium hydrogen phosphate buffer, followed by a cation exchange clean-up. For bovine 
muscle, the analytes were extracted with an acidified potassium hydrogen phosphate buffer 
followed by a cation exchange clean-up. Feed samples were extracted with a mixture of 0.02 
M sulphuric acid and methanol (90:10). The supernatant was filtered and analysed. 
The enzymatic hydrolyses was done by using β-glucoronidase, which meant that if any results 
were obtained it would be for both the parent and metabolised salbutamol fractions.  This is 
not the standard practice as parent salbutamol should be the marker residue for monitoring 
purposes. At the time of the study this was however the standard method of analysis for β-AA, 
including zilpaterol and ractopamine. 
The Limit of Quantification (LOQ) for the method was 3 µg/kg. The method was found to be 
selective for R- and S-salbutamol in fat, kidney, liver and muscle.  The method accuracy was 
confirmed using spiked quality control samples, which was run with every batch.  Repeatability 
was confirmed with the use of six replicates of each matrix at both 2 and 5 ppb, which was run 
with every batch. 
As R-salbutamol is metabolised through glucuronide conjugation in animals and the 
metabolite is not active (Martin, Hobson, Page, & Harrision, 1971), the parent salbutamol 
fraction is usually considered for residue detection and is the marker residue for residue 
analysis.  This is in accordance with the marker residues accepted for both zilpaterol (EFSA, 
2016) and ractopamine (EFSA, 2009). 
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4.2.11 Statistical Analysis of Data 
A primary statistical method to determine the withdrawal period from each of the body tissues 
is described in the guidelines on MRL’s and Withdrawal Periods by the Medicines Control 
Council of South Africa (MCC) (MCC, 2004). 
The protocol describes the conventional statistical methods based on a regression analysis to 
be applied for the determination of withdrawal periods.  With all residue results below the LOQ 
statistical analysis were not possible.   
To calculate the Theoretical Maximum Daily Intake (TMDI) from any residue results the 
average residue, as determined at each withdrawal time point, is used for each animal tissue 
(i.e. liver, muscle, kidney and fat) and multiplied with the food consumption factor (CF) as 
determined by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) in their 34th 
report entitled “Evaluation of Certain Veterinary Drug Residues in Food” (JECFA, 1989).   
The consumption factor for each tissue type is summarised in Table 4.3. 
Table 4.3: Food Consumption Factors for each tissue type as defined by JECFA 
Tissue Daily Intake 
Muscle 300 g 
Liver 100 g 
Kidney 50 g 
Fat 50 g 
A one-sided upper tolerance limit or upper confidence limit (UCL) is then calculated by adding 
the calculated theoretical intake of residues in the animal tissue and adding the product of the 
standard deviation (SD) with the g™ factor. 
𝑈𝐶𝐿 = 𝑚𝑒𝑎𝑛 +  (𝑔™ × 𝑆𝐷) 
Where: 
g™ = A factor for calculating a one-sided tolerance estimate of conformance with a given 
threshold and confidence level.  
The g™ factor is based on the number of animals used at each time point in the residue kinetic 
study and the accepted statistical significance of the data as well as the statistical confidence. 
MCC has accepted the use of a 95% statistical significance with a 90% statistical confidence 
(MCC, 2004). The table with the relevant g™ factors is published in the MCC guidelines on 
MRL’s and Withdrawal Periods (MCC, 2004).  
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Using the sample size (N = 6) in this trial at each time point, the g™ parameter applicable for 
this trial equals 3.066. 
4.3 Results and Discussion 
As the feed used in the trial was spiked three time per day with the R-salbutamol, it had to be 
confirmed that the feed was free from R-salbutamol or any other β-AA. Feed was tested for 
R-salbutamol and zilpaterol and it was confirmed that the feed did not contain any beta-
agonist. 
The average body weight at the start of the trial was 356 kg. Animals were not weighed during 
the trial as the trial was not considered to be a growth performance trial due to restricted 
feeding.  
There were no R-salbutamol related physical signs (tremors and restlessness), often 
associated with β-AA ingestion (Wagner, Morstrom, Hammer, Thorson, & Smith, 2008), 
recorded during the daily general health observations of the animals in this study.  
Nasal discharge was recorded in two animals in group A (control group), one animal in group 
B and one animal in group C. Nasal discharge was similar in nature in all animals and was 
transient and resolved without treatment. Nasal discharge in feedlot cattle may be as a result 
of dust in the feed or may be associated with apparent bovine respiratory disease 
(Montgomery, et al., 2009; Taylor, Fulton, Lehenbauer, Step, & Confer, 2010). 
All tissue residue results were below the limit of quantification (LOQ) of 3 μg/kg, except for 
one muscle sample at 48 hours (0.037 mg salbutamol/kg muscle). 
This value is however ignored and viewed as a laboratory anomaly and disregarded from the 
data set according to the Dixon’s Q-test.  
Qexp = 1 
and therefore 
Qexp > Qcrit (CL=95%) > 0.625 (N=6). 
The theoretical maximum intake for humans consuming beef treated with R-salbutamol could 
therefore not be calculated from the study data.  In a similar study Zhang, et al. (2017) 
investigated the residues of parent salbutamol and that of its metabolites in cattle following 
racemic salbutamol treatment at 0.15 mg/kg BWt for 21 days. Residues were detected in all 
tissue (liver, kidney, fat and muscle) at varying levels at zero withdrawal.  Liver had the highest 
residue level, followed by kidney, fat and muscle (Table 4.4).  
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Table 4.4: Parent salbutamol residue concentration in cattle tissue at zero withdrawal (μg/kg) (Zhang, 
et al., 2017) 
R-salbutamol (μg/kg in tissue) 
Muscle Kidney Liver Fat 
13.92 32.20 53.69 31.16 
Zhang et al. (2017) investigated the residues for salbutamol in the liver and kidney and 
determined that only 9.9% of the total salbutamol residues detected were parent salbutamol 
(53.69 μg/kg parent salbutamol vs. 547.52 μg/kg total salbutamol) in the liver at zero-day 
withdrawal. In kidney, 35.5% of total salbutamol residues were present as parent salbutamol 
(32.50 μg/kg parent salbutamol vs. 91.55 μg/kg total salbutamol) at zero-day withdrawal, 
indicating rapid metabolism of salbutamol in cattle. The average concentration of parent 
salbutamol in the liver of the cattle was lower (53.69 μg/kg) at zero withdrawal in cattle than 
the concentration of parent salbutamol reported in lambs (75.23 μg/kg) following 7 hours 
withdrawal (Chapter 3).  However, total salbutamol (parent + metabolite) concentration in 
cattle (547.52 μg/kg) was three times higher in the liver after zero withdrawal compared to 
total salbutamol concentration detected in lambs (181.27 μg/kg) after 7 hours withdrawal 
(Chapter 3).  Racemic salbutamol was used in the cattle trial, in comparison to the R-
salbutamol in lambs.  It has been shown in humans that R-salbutamol has a shorter half-life 
compared to the racemic mixture (Boulton & Fawcett, 1996).  The difference in withdrawal 
time between the cattle and lamb study should be factored in when comparing this data, as 
salbutamol is rapidly excreted from the body following withdrawal.  Zhang et al. (2017) 
reported a rapid decline in the urine concentration of parent salbutamol from day zero (1654.4 
ng/ml) to day-3 (<LOQ of 0.5 ng/ml) following withdrawal. 
The higher levels of salbutamol residues in the study by Zhang et al. (2017) in muscle, kidney 
and fat raises the question if salbutamol is metabolised differently in cattle compared to lambs. 
The difference in rate of metabolism in R-salbutamol vs. racemic salbutamol observed by 
Boulton and Fawcett (1997) would indicate that the residue profile may differ in R-salbutamol 
compared to racemic salbutamol. The low ratio of parent salbutamol to total salbutamol 
indicated a rapid metabolism of salbutamol (Zhang, et al., 2017).   
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The residue data from a trial performed by Fawcett et al. (2004) in chickens, confirms the 
stereo-selective metabolism of racemic salbutamol vs. R-salbutamol.  At zero-withdrawal, 
chickens fed 10 ppm racemic salbutamol compared to 5 ppm R-salbutamol had much higher 
R-salbutamol residues levels present in liver (55.2 µg/kg vs 34.1 µg/kg), fat (7.2 µg/kg vs. 5.7 
µg/kg) and leg muscle (14.2 µg/kg vs. 11.7 µg/kg), confirming the competition between the 2 
enantiomers for the enzymes for metabolism (Boulton & Fawcett, 1997). 
In a residue study performed with zilpaterol fed at 0.15 mg/kg BWt for 4 days in cattle, residues 
were reported in the liver, muscle and kidney at 24 hours withdrawal, however, no residues 
were detected at 48 hours withdrawal in the muscle and none at 96 hours withdrawal in the 
liver and kidneys (Boison, Ramos, Samders, Chicoine, & Scheid, 2013).  This is in contrast 
with a study by Morris (1997) where residues were still detected in muscle after a 7-day 
withdrawal in cattle fed zilpaterol for 50 days at 0.15 mg/kg BWt.  The difference in the time 
following withdrawal of zilpaterol and salbutamol where residues are still detected in muscle, 
indicates a difference in the rate of metabolism between the two molecules and therefore a 
difference in the half-life of the two β-AA’s.  Shelver and Smith (2006) determined the half-life 
of zilpaterol to be 15.3 ± 1.8 hours in sheep. No pharmacokinetic work has been performed 
with R-salbutamol in cattle and sheep to date.   
The total average daily intake for humans consuming beef tissue from R-salbutamol treated 
cattle can be calculated using the data reported by Zhang (2017), by using the food 
consumption factors for each tissue as set out by JECFA (2000) described in Chapter 3. The 
calculation is summarised in Table 4.5. 
Table 4.5: Calculation of average daily intake of salbutamol in humans at zero-day withdrawal 
Tissue Average parent 
Salbutamol concentration 
(μg/kg) * 
Food consumption 
factors 
Average residue intake 
(μg/person) 
Muscle 13.92 300 g 4.18 
Liver 53.69 100 g 5.37 
Kidney 32.20 50 g 1.61 
Fat 31.16 50g 1.56 
Total salbutamol intake per day in humans 12.72 
* Data from Zhang et al. (2017)
This average human intake value calculated from the cattle data is slightly higher than the 
TMDI calculated from salbutamol residue data in lambs (Chapter 3). The possible explanation 
for the difference is that the result in cattle was obtained following a zero-day withdrawal vs. a 
7-hour withdrawal in the lamb study. The average intake per day for humans calculate to 
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7.33% of the Average Daily Intake (ADI) of 180 μg, derived from the Acute Reference Dose 
(ARfD for R-salbutamol, which indicates that at zero withdrawal, the residue levels in bovine 
tissue will be safe for human consumption.   
The study of Zhang, et al. (2017) was however performed using racemic salbutamol and not 
R-salbutamol. As previously indicated, R-salbutamol metabolises much quicker and is less 
bioavailable than the racemic molecule (Boulton & Fawcett, 1996b), this could possibly explain 
the lack of residues detected in the cattle treated with R-salbutamol. 
The inability to detect any salbutamol residues in the current study can be attributed to either 
the possible quicker metabolism and excretion of R-salbutamol in cattle, or the use of the 
HPLC-DAD method. Liquid chromatography tandem mass spectrometry (LC-MS/MS) is 
currently the preferred method for β-AA detection used for zilpaterol (EFSA, 2016) and 
ractopamine (EFSA, 2009) residue detection as it is more sensitive and specific than the 
HPLC-DAD method (Marquet, 2002).  At the time (2010) this was however the only method 
available at the Agricultural Research Council Residue Laboratory at Onderstepoort.  The 
residues detected in the salbutamol residue study in sheep can be attributed to either a 
difference in the metabolism rate of R-salbutamol in sheep, or the use of LC-MS/MS, instead 
of the HPLC-DAD method. 
4.4 Conclusion 
R-salbutamol use in feedlot cattle is safe for use in the target animal as no physical adverse 
events were observed with the addition of R-salbutamol in the feed.  
No residues were detected in the cattle R-salbutamol residue study possibly due to either the 
faster metabolism of R-salbutamol in cattle, or the less reliable and specific method of HPLC-
DAD used during sample analysis.  The data from a residue study performed using racemic 
salbutamol in cattle indicates that the residues present in beef after treatment with salbutamol 
is safe for human consumption.  
The lack of method sensitivity in the analysis for salbutamol residues in the current study 
warrants a repeat of the study using a more sensitive analysis method (LC-MS/MS) as well as 
analysing samples for both parent and total salbutamol. 
The possibility of the quicker metabolism and excretion of R-salbutamol in cattle warrants 
pharmacokinetic studies of R-salbutamol in cattle to determine the half-life and elimination 
kinetics. 
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CHAPTER 5 
GENERAL CONCLUSION AND RECOMMENDATIONS 
The aim of these investigations was to determine the levels of the marker residue, parent 
salbutamol, and total salbutamol (parent + metabolite) in lambs and cattle treated with R-
salbutamol during the feedlot finishing phase.   
5.1 Human Safety 
A comprehensive human risk assessment was done for R-salbutamol and a subsequent Acute 
Reference Dose (ARfD) of 3 µg/kg BWt for humans was determined to be the upper safe 
intake level where no acute adverse events would be observed.  The ARfD were used as the 
upper limit for the Acceptable Daily Intake (ADI), which was set at 0 - 3 µg/kg BWt.  In 
comparison with the ADI for zilpaterol of 0 - 0.04 µg/kg BWt (EFSA, 2016) and the ADI for 
ractopamine of 0 - 1 µg/kg BWt (EFSA, 2009), R-salbutamol can therefore be classified as the 
safer of these beta-agonist for use in animal production, with a high safety margin in humans. 
5.2 Lamb Residues 
In the lamb residue study (Chapter 3), the highest concentration of residues was detected in 
the liver, followed by the kidney, muscle and fat.  Parent and total salbutamol residues in the 
liver, kidney, muscle and fat declined rapidly from 7 hours to 24 hours after withdrawal of R-
salbutamol in the feed. Less than half of the residues detected in all the tissue analysed were 
parent salbutamol indicating rapid metabolism and excretion of R-salbutamol after ingestion. 
This also suggests a low oral bioavailability for R-salbutamol with a large portion of active 
parent salbutamol being metabolised in the gut lining and liver through the first pass effect. 
Further investigation into the pharmacokinetics of oral vs. intravenous administration of R-
salbutamol in feedlot lambs will shed more light on the absorption, distribution, metabolism 
and excretion (ADME) of R-salbutamol. 
The Theoretical Maximum Daily Intake (TMDI) for humans calculated from the lamb residue 
data in the liver, kidney, muscle and fat indicated that the residues in lamb tissue after 7 hours 
withdrawal of R-salbutamol is far below the ADI calculated for humans. The TMDI is 8.98% of 
the ADI at 7 hours after R-salbutamol withdrawal.  It is therefore safe to recommend a zero 
withdrawal for Salbutamate 10% (R-salbutamol sulphate) when used according to the label 
recommendations. 
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No adverse pharmacological effects were detected visually in lambs administered R-
salbutamol, suggesting that R-salbutamol is safe for use at the recommended inclusion levels 
in feedlot lamb diets. There was no difference in heart rate between the non-medicated and 
medicated period. There was a significant difference in the respiratory rate following R-
salbutamol inclusion, possibly due to lower respiratory tract infection.  The significant increase 
in rectal temperature of the lambs was not of clinical significance as it remained within the 
normal range of rectal temperature for sheep. Heart rate would normally be expected to 
increase with β-agonist administration as it is a cardio active drug. The effect of R-salbutamol 
on the increased respiratory rate and rectal temperature should however be investigated 
further.   
5.3 Cattle Residues 
In the cattle residue study (Chapter 4), no residues were detected at <12, 24 or 48 hours after 
withdrawal. The HPLC-DAD method used to determine the residues is not the preferred 
method for beta-agonist analysis.  Further investigation into residue depletion in cattle using 
the LC-MS/MS method is therefore recommended.   
Residue levels in a cattle study by Zhang et al. (2017), medicated with racemic salbutamol, 
indicates rapid metabolism of salbutamol in cattle as is the case with lambs.  The difference 
in the ratio between parent salbutamol and total salbutamol may indicate difference in the rate 
of metabolism of salbutamol between cattle and sheep.  The study by Zhang et al. (2017) used 
racemic salbutamol and it is known that R-salbutamol metabolises faster than S-salbutamol 
and R-salbutamol is less bioavailable compared to S-salbutamol in humans (Boulton & 
Fawcett, 1996b). Determination of the absorption, distribution, metabolism and excretion 
(ADME) of R-salbutamol through pharmacokinetic studies of oral vs. intravenous 
administration of R-salbutamol in feedlot cattle is therefore required. 
No observable adverse events were noted during the trial period, although this cannot be used 
to conclude that R-salbutamol is safe for the target animal.  Physical monitoring of animals is 
required in future studies on the use of R-salbutamol in cattle.  Nonetheless, as animal welfare 
has become an important factor for consumers, the effect of R-salbutamol on the heart rate, 
respiratory rate and rectal temperature should be further investigated to determine if R-
salbutamol has a similar effect in cattle compared to observed effects with the use of other β-
AA. 
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5.4 Maximum Residue Limit (MRL) 
From the lamb study, the MRL for R-salbutamol in animal tissue can safely be set at 6.5 μg/kg 
in meat/muscle, 300 μg/kg in liver, 40 μg/kg in kidney and 13 μg/kg in fat.  These values would 
equate to a TMDI of almost 9% of the ADI for R-salbutamol in comparison to the MRL values 
for zilpaterol that equates to a TMDI at 30% of ADI (EFSA, 2016) and Ractopamine with a 
TMDI at 25% of ADI (EFSA, 2009). 
5.5 Final Conclusion 
The results of this study indicate that R-salbutamol, used according to label recommendations, 
is safe for both the target species (feedlot lambs and cattle) as well as for humans consuming 
beef and lamb tissue from animals treated with R-salbutamol with a zero-day withdrawal. 
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